UNIVERSITÀ DEGLI STUDI DI ROMA "TOR VERGATA"

FACOLTA' DI MEDICINA e CHIRURGIA

DOTTORATO DI RICERCA IN MICROBIOLOGIA MEDICA ed IMMUNOLOGIA

XXI Ciclo

"Effect of nucleoside and nucleotide analogues on reverse transcriptase activity in primary isolates from HTLV-1 infected patients."

Arianna Ascolani

A.A. 2008/2009

Docente Tutor: Prof. Beatrice Macchi

Coordinatore: Prof. Enrico Garaci

INDEX

7. ACKNOWLEDGEMENTS

1. INTRODUCTION

1.1 RETROVIRUSES

Retroviruses comprise a large and diverse family of enveloped RNA viruses defined by common taxonomic denominators that include structure, composition, and replicative properties (Coffin J.M., 1996).

Retroviruses can be broadly divided into two main categories, simple and complex, distinguishable by the organization of their genomes (Murphy et al. 1994). All retroviruses contain three major coding domains with information for virion proteins: *gag*, which directs the synthesis of internal virion proteins that form the matrix, the capsid, and the nucleoprotein structures; *pol*, which contains the information for the reverse transcriptase and integrase enzymes; and *env*, from which are derived the surface and transmembrane components of the viral envelope protein. An additional, smaller, coding domain present in all retroviruses is *pro*, which encodes the virion protease. Simple retroviruses usually carry only this elementary information, whereas complex retroviruses code for additional regulatory proteins derived from multiply spliced messages. Retroviruses are further subdivided into seven groups defined by evolutionary relatedness, each with the taxonomic rank of *genus* (see Table 1). Five of these groups represent retroviruses with oncogenic potential (formerly referred to as oncoviruses), and the other two groups are the lentiviruses and the spumaviruses. All oncogenic members except the human T-cell leukemia virus–bovine leukemia virus (HTLV-BLV) genus are simple retroviruses. HTLV-BLV and the lentiviruses and spumaviruses are complex.

Retroviruses in different genera show little sequence similarity at the nucleotide level, as measured experimentally by standard biochemical techniques, and only limited amino acid similarity except in reverse transcriptase. In the approximately 175 amino acid residues that constitute the most conserved part of reverse transcriptase, viruses in different genera

show identity at about one third to two thirds of the residues (see Figure 1). Generally, viruses within a genus show identity at more than two thirds of these residues. However, there are exceptions to these rules, reflecting the imperfections of the classification system, restricted sampling of existing retroviruses, and perhaps unknown evolutionary constraints in some genera. For example, there are some members of the lentiviral genus with less similarity in the reverse transcriptase sequence than suggested by these approximations.

HTLV-1 and HTLV-2 both belong to the genus Retrovirinae HTLV-BLV, and have sequence homology of 65%. In recent studies, the terms "HTLV-3" and "HTLV-4" have been used to describe recently characterized viruses (Mahieux R. and Gessain A., 2005; Calattini S. *et al.*, 2006). These viruses were discovered in 2005 in rural Cameroon, and were apparently transmitted from monkeys to hunters of monkeys through bites and scratches. HTLV-3 is similar to STLV-3 (*Simian T-lymphotropic virus 3*), but HTLV-4 does not resemble any known virus. It is not yet known how much further transmission has occurred among humans, or whether the viruses can cause disease. The use of these names can cause some confusion, because the name *HTLV-3* was the former name of HIV in early AIDS literature, but has since fallen out of use. Also, the name *HTLV-4* has been used to describe HIV-2. The human imunodeficiency virus type 1 (HIV-1) is currently included in the group of *Lentivirus*. Although HTLV-1 and HIV-1 have many similarities in the mechanisms of transmission, including the target cell (lymphocytes CD4 +), and in the mechanisms of viral replication and messengers expression through multiple splicing events, they have a low homology of sequence. HTLV-1 causes also the immortalization of infected lymphocytes, while HIV-1 is cytopathic, which determines the death of infected cells (Del Mistro A. *et al.*, 1986). Also, in vivo HIV is associated with stages of viraemia, while infection with HTLV-1 is mainly characterized by the absence or almost of viraemia.

Genus	Type Species	Virion morphology[a]
1. Alpharetrovirus[b]	*Avian leukosis virus*	central, spherical core "C particles"
2. Betaretrovirus	*Mouse mammary tumour virus*	eccentric, spherical core "B particles"
3. Gammaretrovirus	*Murine leukemia virus*	central, spherical core "C particles"
4. Deltaretrovirus	*Human T-lymphotropic virus* *Bovine leukemia virus*	central, spherical core
5. Epsilonretrovirus	*Walleye dermal sarcoma virus*	cylindrical core "D particles"
6. Lentivirus	*Human immunodeficiency virus* *Simian immunodeficiency virus*	cone-shaped core
7. Spumavirus	*Chimpanzee foamy virus*	central, spherical core

[a] Distinctive features seen in transmission electron micrographs.
[b] Groups 1 through 5 are presently (and, hopefully, temporarily) designated by the awkward descriptive terms listed in the table, awaiting the proposal of more succinct appellations by the International Committee on taxonomy of viruses.

Table 1: Retrovirus classification

Figure 1. Phylogeny of Retroviruses: genera that include endogenous genomes are marked with an asterisk (from Weiss R.A., 2006).

1.2 HTLV-1

HTLV-1 is an acronym for the human T-cell lymphotropic virus type 1, also called the Adult T-cell lymphoma virus type 1. HTLV was discovered in 1977 in Japan. The virus was first isolated by Drs. Bernard Poiesz and Francis Ruscetti and their co-workers in the laboratory of Robert C. Gallo at the NCI (Poiesz B.J. *et al.*, 1980;1981). HTLV was the first identified human retrovirus (Johnson J.M. *et al.*, 2001; Shuh M. and Beilke M., 2005). HTLV-1 infects 20 million people worldwide where the majority of infected individuals are asymptomatic carriers of the virus (Verdonck K. *et al.*, 2007). However, in a small percentage of infected people this agent has also been demonstrated to be the aetiological agent in patients with adult T-cell leukemia/lymphoma (ATLL; Poiesz B.J. *et al.*, 1980) and a chronic, progressive neurologic disease termed HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP; Gessain A. *et al.*, 1985; Osame M. *et al.*, 1987).

1.3 HTLV-1 BIOLOGY

1.3.1 Epidemiology

Over the course of nearly 25 years, the epidemiology of human T-lymphotropic virus type 1 (HTLV-1) has progressively developed. The geographic distribution of the virus has been defined, although some puzzles persist such as the high prevalence in southwestern Japan but low prevalence in neighboring regions of Korea, China and eastern Russia, and seemingly isolated pockets of infection in Iran. Although the exact number of HTLV-1 seropositive individuals in the world is not known, it is estimated that about 15–20 millions persons live with HTLV infection worldwide (de The G. and Kazanji M., 1996). The seroprevalence rates differ, according to geographic area, the socio-demographic composition of the population studied and individual risk behaviors. For example,

prevalence rates as high as 37.0% were reported in small, selected populations from some areas in southwestern Japan (Yamaguchi K., 1994; Mueller N. *et al.*, 1996) as compared to very low prevalence rates (0.0039%) among French blood donors (Courouce A.M. *et al.*, 1993). However, information on prevalence rates from representative samples of the general population is rare. Most data on HTLV-1 prevalence rates are from studies in generally low-risk blood donors or selected population groups (pregnant women, neurological or hematological patients, relatives of infected individuals, specific native and sometimes isolated population groups, intravenous drug users (IDU) and sex workers) that are certainly not representative of the general population (Mueller N., 1991; Ferreira O.C. *et al.*, 1997; Manns A. *et al.*, 1999). For non endemic geographic areas such as Europe and North America, HTLV-1 infection is mainly found in immigrants from endemic areas, their offspring and sexual contacts, among sex workers and IDU. For blood donors in North America and Europe, seroprevalence is very low, for example, 0.01–0.03% in USA and Canada (Williams A.E *et al.*, 1988; Murphy E.L. *et al.*, 1991; Chiavetta J.A. *et al.*, 2003), 0.002% in Norway (Stigum H. *et al.*, 2000) and 0.0056% in Greece (Tseliou P.M. *et al.*, 2003). Data from studies of pregnant women may better reflect prevalence rates of the general population. Prevalence rates for HTLV-1 and II were six fold higher in pregnant women than in blood donors in the United Kingdom (Taylor G.P. *et al.*, 2005). A study on 6754 pregnant women in Salvador, Brazil found 0.84% to be seropositive (Bittencourt A.L. *et al.*, 2001).

Figure2: Countries with endemic HTLV-1, defined as prevalence between 1 and 5% in some populations, are shown in dark brown. Countries with reports of low prevalence (less than 1% in some groups), due mainly to immigration from endemic areas, are shown in tan color. (from Proietti F.A. *et al.*, 2005).

1.3.2 Receptor and transmission of HTLV-1

HTLV-1 can infect various types of cells, such as T-lymphocytes, B-lymphocytes, monocytes and fibroblasts (Koyanagi Y *et al.*, 1993). Glucose transporter 1 (GLUT-1) has been identified as a receptor for HTLV-1 and this receptor is ubiquitously expressed on cell surfaces (Manel N *et al.*, 2003). However, the HTLV-1 provirus is mainly detected in CD4-positive lymphocytes, with about 10% in CD8-positive T-lymphocytes (Yasunaga J. *et al.*, 2001). This situation possibly arises because Tax mainly induces the increase of CD4-positive T-lymphocytes *in vivo* by enhanced proliferation and suppressed apoptosis.

In HTLV-1-infected individuals, no virions are detected in the serum. In addition, the infectivity of free virions is very poor compared with that of infected cells. These findings suggest that HTLV-1 is spread by cell-to-cell transmission, rather than by free virions. *In vitro* analyses of HTLV-1-infected cells revealed that HTLV-1-infected cells form "virological synapses" with uninfected cells. Contact between an infected and a target cell induces the accumulation of the viral proteins Gag and Env, viral RNA and microtubules, and the viral complex subsequently transfers into the target cell (Igakura T. *et al.*, 2003;see Figure 3).

HTLV-1 is mainly transmitted via three routes: 1) mother-to-infant transmission (mainly through breast feeding) (Hino S., 2003); 2) sexual transmission (mainly from male-to-female); and 3) parenteral transmission (blood transfusion or intravenous drug use) (Blattner W.A. and Gallo R.C., 1994). In either route, HTLV-1-infected cells are essential for transmission. This was supported by the findings that fresh frozen plasma from carriers did not cause transmission (Okochi K. et al., 1984) and freeze-thawing of breast milk reduced vertical transmission (Ando Y. et al., 2004).

HTLV-1-infected T cell

Uninfected T cell

HTLV-1 provirus

Formation of
virological synapse

Viral RNA
pre-integration complex

MTOC

LFA1   Tax
ICAM1   Gag

Newly HTLV-1-infected T cell

Nature Reviews | Cancer

Figure 3: This figure illustrates the cell–cell contact required to create a virological synapse through which the viral genome is transmitted from one cell to another. The roles played by lymphocyte function-associated antigen 1 (LFA1), and intercellular adhesion molecule 1 (ICAM1) in forming cell–cell contact are shown. Tax contributes to the formation of a microtubule organizing centre (MTOC) (from Matsuoka M. *et al.*, 2007).

1.3.3 Structure and genomic expression regulation

The HTLV-1 provirus has a similar structure to other retroviruses: a long terminal repeat (LTR) at both ends and internal sequences such as the *gag*, *pol* and *env* genes. A characteristic of HTLV-1 is the presence of the pX region, which exists between *env* and the 3'-LTR. This region encodes several accessory genes, which include the *tax*, *rex*, *p12*, *p21*, *p30*, *p13* and *HBZ* genes (see Figure 4). Among these, the *tax* gene plays central roles in viral gene transcription, viral replication and the proliferation of HTLV-1-infected cells. Tax enhances viral gene transcription from the 5'-LTR via interaction with cyclic AMP responsive element binding protein (CREB). Tax also interacts with cellular factors and activates transcriptional pathways, such as NF-κB, AP-1 and SRF (Yoshida M., 2001; Franchini G. *et al.*, 2003; Jeang KT *et al.*, 2004; Azran I. *et al.*, 2004). For example, activation of NF-κB induces the transcription of various cytokines and their receptor genes, as well as anti-apoptotic genes such as *bcl-xL* and *survivin* (Tsukahara T *et al.*, 1999; Nicot C et al., 2000; Kawakami H *et al.*, 2005). The activation of NF-κB has been demonstrated to be critical for tumour genesis both *in vitro* and *in vivo* (Yamaoka S *et al.*, 1996; Portis T *et al.*, 2001). On the other hand, Tax variant without activation of NF-κB has also been reported to immortalize primary T-lymphocytes *in vitro* (Rosin O *et al.*, 1998), suggesting that mechanisms of immortalization are complex. In addition to NF-κB, activation of other transcriptional pathways such as CREB by Tax should be implicated in the immortalization and leukemogenesis.

Tax also interferes with the functions of p53, p16 and MAD1 (Suzuki T *et al.*, 1999). These interactions enable HTLV-1-infected cells to escape from apoptosis, and also induce genetic instability. Although inactivation of p53 function by Tax is reported to be mediated by p300/CBP (Van Orden, K *et al.*, 1999; Ariumi, Y *et al.*, 2000) or NF-κB activation (Pise-Masison, CA *et al.*, 2000), Tax can still repress p53's activity in spite of loss of

p300/CBP binding or in cells lacking NF-κB activation, indicating the mechanism of p53 inactivation by Tax needs further investigation (Geiger TR *et al.*, 2008).

Although Tax promotes the proliferation of infected cells, it is also the major target of cytotoxic T-lymphocytes (CTLs) *in vivo*. Moreover, excess expression of Tax protein is considered to be harmful to infected cells. Therefore, HTLV-1 has redundant mechanisms to suppress Tax expression. Rex binds to Rex-responsive element (RxRE) in the U3 and R regions of the 3'-LTR, and enhances the transport of the unspliced *gag*/*pol* and the singly spliced *env* transcripts. By this mechanism, double-spliced *tax*/*rex* mRNA decreases, resulting in suppressed expression of Tax. On the other hand, p30 binds to *tax*/*rex* transcripts, and retains them in the nucleus (Nicot C. *et al.*, 2004). The *HBZ* gene is encoded by the complementary strand of HTLV-1, and contains a leucine zipper domain. HBZ directly interacts with c-Jun or JunB (Basbous, J *et al.*, 2003), or enhances their degradation (Matsumoto, J *et al.*, 2005), resulting in the suppression of Tax-mediated viral transcription from the LTR.

Transforming growth factor-β (TGF-β) is an inhibitory cytokine that plays important roles in development, the immune system and oncogenesis. Since TGF-β generally suppresses the growth of tumour cells, most tumour cells acquire escape mechanisms that inhibit TGF-β signalling, including mutations in its receptor and in the Smad molecules that transduces the signal from the receptor. Tax has also been reported to inhibit TGF-β signalling by binding to Smad2, 3 and 4 or CBP/p300 (Mori N. *et al.*, 2001; Lee D.K. *et al.*, 2002). Inhibition of TGF-β signalling enables HTLV-1-infected cells to escape TGF-β-mediated growth inhibition.

ATL cells have been reported to show remarkable chromosomal abnormalities (Kamada N. *et al.*, 1992), which should be implicated in the disease progression. Tax has been reported to interact with the checkpoint protein MAD1, which forms a complex with MAD2 and

controls the mitotic checkpoint. This functional hindrance of MAD1 by Tax protein causes chromosomal instability, suggesting the involvement of this mechanism in oncogenesis. Recently, Tax has been reported to interact with Cdc20 and activate Cdc20-associated anaphase-promoting complex, an E3 ubiquitin ligase that controls the metaphase-to-anaphase transition, thereby resulting in mitotic abnormalities (Endo K. *et al.*, 2002).

In contrast to HTLV-1, HTLV-2 promotes the proliferation of CD8-positive T-lymphocytes *in vivo*. Although it was first discovered in a patient with variant hairy cell leukemia, HTLV-2 is less likely to have oncogenic properties since there is no obvious association between HTLV-2 infections and cancers. Regardless of the homology of their *tax* sequences, the oncogenic potential of Tax1 (HTLV-1 Tax) is more prominent than that of Tax2 (HTLV-2 Tax). The most striking difference is that Tax2 lacks the binding motif at C-terminal end to PDZ domain proteins, while Tax 1 retains it. When the PDZ domain of Tax1 is added to Tax2, the latter acquires oncogenic properties in the rat fibroblast cell line Rat-1, indicating that this domain is responsible for the transforming activity of HTLV-1 (Hirata A. et al., 2004).

To understand the pleiotropic actions of Tax protein more clearly, transcriptome analyses are essential. The transcriptional changes induced by Tax expression have been studied using DNA microarrays, which revealed that Tax upregulated the expression of the mixed-lineage kinase MLK3. MLK3 is involved in NF-κB activation by Tax as well as NIK and MEKK1 (Ng P.W. *et al.*, 2001). In addition to transcriptional changes, Tax is also well known to interact with cellular proteins and impair or alter their functions. For example, proteomic analyses of Tax-associated complexes showed that Tax could interact with cellular proteins, including the active forms of small GTPases, such as Cdc42, RhoA and Rac1, which should be implicated in the migration, invasion and adhesion of T-cells, as well as in the activation of the JNK pathway (Wu K *et al.*, 2004).

Many questions pertaining to *in vivo tax* and virus expression are currently unanswered. Bangham and their coworkers used deuterated glucose for labeling patients' lymphocytes to check the *in vivo* effect of *tax*/HTLV expression on lymphocyte population dynamics. He sobserved increased proliferation of CD4$^+$CD45RO$^+$ and CD8$^+$CD45RO$^+$ T-lymphocytes in HTLV-1–infected persons compared with controls, with the additional production of 10^{12} lymphocytes per year in the former. The *in vivo* proliferation rate of CD4$^+$CD45RO$^+$ cells correlated with *tax* expression (measured *ex vivo*), supporting a physiologic role (directly or indirectly) for this viral oncoprotein in the proliferation of infected cells (Asquith B. *et al.*, 2007).

Figure 4: A scheme of the HTLV-1 genome, alternatively spliced mRNAs, and putative proteins encoded by each mRNA is shown. ORFs are indicated by boxes (from Nicot C. *et al.*, 2005).

1.4 DISORDER ASSOCIATED WITH HTLV-1

Although still not fully clarified the molecular mechanisms that occur after infection to determine the onset of various diseases associated with HTLV-1, it seems that alteration of cellular genes and tissue damage induced by the immune response to the virus could play an important role in the pathogenesis of the HTLV-1 associated diseases. As previously described, the ATLL is a T-cell leukemia while the TSP / HAM is a neurological disorder characterized by destruction of cells of the central nervous system and inflammatory processes.

1.4.1 Adult T-cell leukaemia/lymphoma (ATLL)

Adult T-cell leukaemia/lymphoma (ATLL) is a mature T-cell neoplasm of post-thymic lymphocytes aetiologically linked to the human T-cell lymphotropic virus, HTLV-1, and with a distinct geographical distribution (Matutes E., 2007). The disease manifests with leukaemia in greater than two thirds of patients, while the remaining patients have a lymphomatous form. ATLL affects almost exclusively adults and is extremely rare in children, although a few cases in childhood have been described (Pombo de Oliveira M.S. *et al.*, 1990). The median age is around the mid-60s and there is no gender prevalence. Familial ATLL has been documented in Japan, USA and in England (Yamaguchi K. *et al.*, 1985; Matutes E. *et al.*, 1995); it is unknown whether a genetic predisposition plays a role in the development of the disease in such cases. In addition, ATLL may coexist or follow other HTLV-1 induced non-neoplastic diseases such as tropical spastic paraparesis (Cartier L. *et al.*, 1995). Depending on the disease manifestations, ATLL is classified into several forms: acute, chronic, smouldering and lymphoma (Shimoyama M., 1991). The most common form of presentation is acute, which is seen in around 65% of patients. This is characterised by the presence of systemic symptoms, organomegaly, in particular

lymphadenopathy, and a leukaemic picture. Hypercalcaemia with or without lytic bone lesions is present in half of these patients and it may develop during disease progression in another third. Skin lesions are seen in close to a half of these patients. The chronic form is characterised by lymphocytosis which may be stable for months or even years, skin manifestations, no organomegaly or small volume lymphadenopathy, absence of hypercalcaemia and normal or only slightly raised lactate dehydrogenase (LDH) (less than twice the upper normal limit value). Patients with smouldering ATLL are usually asymptomatic or manifest skin rashes that respond to topical steroids and/or lung infiltrates; unlike the chronic form, the white blood cell count is normal and there is no lymphocytosis and less than 3% atypical circulating lymphocytes. Less than a third of patients carry lymphoma with no evidence of blood involvement. There are several reports documenting disease progression to the acute form in patients with chronic and smouldering ATLL. Haemophagocytic syndrome as the first sign of transformation has been described in smouldering ATLL (Aouba A. *et al.*, 2004). In addition to the symptoms related to the neoplastic condition, patients with ATLL are immunocompromised and develop opportunistic infections that complicate the disease course and make its management more difficult. Infestation by *Strongyloides stercoralis* is frequent and may be severe and fatal. This association and the fact that a third of the patients with strongyloidiasis and positive serology for HTLV-1 have a clonal integration of the provirus in their lymphocytes, have led to the hypothesis that this parasite plays a role in the development of ATLL in healthy carriers (Yamaguchi K. *et al.*, 1987) .

The immunophenotype of the ATLL cell is that of an activated mature T-lymphocyte. The cells express CD2 and CD5 and often are CD7 negative; CD3 and T-cell receptor (TCR)-β may be down-regulated (weak expression or even negative in the cell membrane); however, the cells express these proteins in their cytoplasm. The most common

immunophenotypic profile is CD4+CD8−, but cases in which cells co-express these two markers or express only CD8 have been described; it has been suggested that CD4+CD8+ cases have a worse clinical course (Tamura K. *et al.*, 1985). The most characteristic immunophenotypic feature of the neoplastic cell is the strong expression of the alpha chain of the interleukin-2 (IL-2) receptor recognised by the monoclonal antibody CD25 (Matutes E., 2007). Such expression is distinctive but not unique to ATLL; it may be seen in other T-cell malignancies, such as T-prolymphocytic leukaemia (T-PLL) and SS (Shyongen Syndrome), although it is expressed at a lower density in these diseases. Other T-cell activation markers such as CD38 and HLA-DR are variably expressed and natural killer (NK) cell markers are, as a rule, negative.The diagnosis of ATLL can be established by integrating the clinical and laboratory features. The morphology of the circulating neoplastic lymphocytes and the immunophenotype are very characteristic of the disease. Histology of the lymph node is not needed for diagnosis in patients with a leukaemic form of ATLL in whom cytology and immunophenotyping are typical of the disease and in whom serum antibodies to HTLV-1 are demonstrable. The diagnosis of the pure lymphomatous forms is more problematic as the histological features of ATLL overlap with those of other T-cell lymphomas. In both leukaemic and lymphomatous forms, HTLV-1 serology is a mandatory investigation. The differential diagnosis includes other mature T-cell malignancies, essentially the cerebriform variant of T-prolymphocytic leukemia (T-PLL), mycosis fungoides and Sjögren syndrome (SS), other peripheral T-cell lymphomas, not specified, and rarely Hodgkin disease and angioimmunoblastic T-cell lymphoma. Patients with smouldering ATLL should be distinguished from healthy carriers of the virus.

The prognosis of ATLL is poor, with a median survival of less than one year for the acute and lymphoma forms. The projected 4-year survival is estimated to be around 5% for these

two clinical variants. Chronic and smouldering ATLL fare better, with a projected 4-year survival of 26.9% and 62% respectively (Shimoyama M., 1992). Clinical form, age, performance status, elevation of LDH, high β2-microglobulin, high serum level of CD25, high serum neuron-specific enolase, the presence of hypercalcaemia and a high proliferative rate are the main prognostic factors (Sadamori N. *et al.*, 1995; Nishimura S. *et al.*, 1995). In the chronic form of ATLL, the proliferative rate of the neoplastic cells measured by Ki-67 expression, albumin levels and LDH appear to distinguish subgroups with favourable and unfavourable prognosis (Shirono K. *et al.*, 1994).

1.4.2 Tropical spastic paraparesis/HTLV-1 associated myelopathy (TSP/HAM)

Tropical spastic paraparesis/HTLV-1 associated myelopathy (TSP/HAM), caused by human T lymphotropic virus type 1 (HTLV-1), has an incidence of 1 case per 100 HTLV-1 infected carriers in highly endemic populations (Kaplan J.E. *et al.*, 1990). The major histopathological characteristic of TSP/HAM is a chronic inflammation of the white and gray matter of the spinal cord followed by a degenerative process that preferentially affects the white matter in the lower spinal cord (Bhigjee A. *et al.*, 1993; Iwasaki Y., 1990). TSP/HAM is characterized by a chronic slowly progressive spastic paraparesis with bladder disturbances, absent or mild sensory loss and low back pain, with seropositivity for HTLV-1 antibodies, in the absence of spinal cord compression (Gessain A. and Gout O., 1985). Despite the more usual presentation characterized by a slow progression, 21.5% of the patients may experience a rapid progression, with severe disability two years after the onset of symptoms. This phenomenon is related to older age of onset, parenteral HTLV-1 transmission route, high viral loads, and high antibody titers (Matsuzaki T. *et al.*, 2001; Nakagawa M. *et al.*, 1995; Toro C. *et al.*, 2003).

The neuropathology of HAM/TSP appears to change gradually during the progression of

the disease. Initially, up to 5 years after onset, the leptomeninges and blood vessels are infiltrated with lymphocytes that penetrate the surrounding parenchyma. Numerous inflammatory cells including both CD8 and CD4 T cells (in equal numbers), B cells, and foamy macrophages are present in damaged areas of the spinal cord parenchyma (Umehara F. *et al.*, 1993). HLA class I and β2-microglobulin are expressed on endothelial cells and infiltrating mononuclear cells (Wu E. *et al.*, 1993; Moore G.R. *et al.*, 1989). HLA class II expression also occurs in the endothelial cells, microglia, and infiltrating mononuclear cells of affected lesions. Later in the disease, immunohistochemical analysis of the affected spinal cord lesions shows the predominance of CD8 T cells. Such lesions also express HLA class I antigens and have HTLV-1–specific CD8 cytotoxic T lymphocytes (CTL) (Levin M.C. *et al.*, 1997). CD8 CTL, thought to represent functionally cytotoxic cells, are observed frequently in active chronic lesions and occasionally in inactive chronic lesions in HAM/TSP patients (Umehara F. *et al.*, 1994). The amount of proviral DNA in HAM/TSP patients correlates with the number of CTL. Inflammatory cells and HTLV-1 proviral DNA decrease with duration of the disease. Since infiltrating CD8 cells are thought to play an important role in the development of HAM/TSP, an effort has been made to localize HTLV-1 in the central nervous system (CNS) of HAM/TSP patients and to determine which cells might serve as targets for inflammatory CD8 cells. HTLV-1 *gag, pX,* and *pol* sequences have been localized to the thoracic cord areas (Yoshioka A. *et al.*, 1993) and are greater in areas of increased CD4 infiltration. HTLV-1 *pX* and *env* sequences have been localized to affected spinal cord (Kira J. *et al.*, 1992; Ohara Y. *et al.*, 1992) and HTLV-1 RNA has been localized to astrocytes (Lehky T.J. *et al.*, 1995). Increased expression of inflammatory cytokines (Umehara F. *et al.*, 1994) and adhesion molecules (Umehara F. *et al.*, 1996) occurs in the spinal cord of HAM/TSP patients with a short duration of disease. As the disease becomes chronic (>5 years), the number of inflammatory cells decreases

substantially. The expression of inflammatory cytokines is also reduced over the duration of the disease and, with the exception of interferon (IFN)-γ, becomes undetectable. Collectively, these findings support the view that inflammatory T lymphocytes (and CD8 cells in particular) may play a critical role in the immunopathogenesis of HAM/TSP (Jacobson S., 2002).

1.5 THERAPY OF HTLV-1 ASSOCIATED DISEASES

1.5.1 Treatment of adult T-cell leukemia/lymphoma

The therapeutic approaches against HTLV-1 are different.

Conventional chemotherapies, such as cyclophosphamide, adriamycin, vincristine and prednisolone (CHOP), comprise the major therapeutics for acute and lymphoma type ATLL (Ishitsuka K. and Tamura K., 2008).

Several new drugs are active against ATLL. For example MST-16, a new oral inhibitor of topoisomerase II induced one complete remission and eight partial remissions in 23 ATLL patients with or without prior therapy (Ohno *et al.*, 1993). In addition, 2'-deoxycoformycin administered alone or in combination with other cytotoxic agents, as well as cladribrine have modest activity against ATLL.

Interferon has modest effects on ATLL and HTLV-1 infected cell lines *in vitro*. Sporadic reports have indicated a clinical response to interferon-α, β or γ by patients with ATLL, but prospective clinical trials of interferon-α, did not confer a significant benefit upon patients with acute and lymphoma type ATLL.

AZT and interferon−α
Arsenic trioxide and interferon-α
Targeting surface molecules on ATLL cells
Anti-CD25 antibody
Anti-CD2 antibody
Anti-CD52 antibody
Anti-CD4 antibody
Anti-CCR4 antibody
Retinoid derivates
Bortezomib

Table 2: Novel therapy for ATLL

Zidovudine, 3'-azide-3'-deoxythymidine (AZT), combined with interferon-α has been suggested as a first line treatment for ATLL. The mechanism of the anti-ATLL effects induced by AZT and interferon-α therapy have not been defined. Intracellular phosphorylation changes AZT into its active form (zidovudine triphosphate; ZDV-TP), which is incorporated into viral DNA and then reverse transcriptase is inhibited via DNA chain termination (Furman P.A. *et al.*, 1986). However, ZDV-TP is reported to be incorporated into cellular DNA *in vitro*. Its ability to inhibit cellular polymerases α and γ is 100-fold less potent than that to inhibit HIV reverse transcriptase (Copeland W.C. *et al.*, 1992). Therefore, ZDV-TP probably does not directly affect cellular DNA. In fact, neither AZT nor interferon-α has direct toxicity against ATLL cell lines and against fresh ATLL cells obtained from patients who achieved complete remission after AZT and interferon-α therapy (Bazarbachi A. *et al.*, 2000). AZT has not yet shown activity against HTLV-1 replication/expansion. Although AZT prevented HTLV-1 transmission when administered at the onset of infection *in vitro*, anti-HTLV-1 activity on already infected cells has not been unequivocally established (Matsushita S. *et al.*, 1987; Macchi B. *et al.*, 1997; Balestrieri E. *et al.*, 2002; Garcia-Lerma J.G. *et al.*, 2001). Despite the absence of supportive evidence, anti-retroviral agents probably do not reduce HTLV-1 provirus load in ATLL patients based on these observations.

Arsenic trioxide is widely used as a second line treatment for acute promyelocytic leukemia (APL). This agent has been suggested to induce partial differentiation by modulating promyelocytic leukemia-retinoic acid receptor α (PML-RARα) protein, and apoptosis by activating caspases against APL cells (Mistry A.R. *et al.*, 2003). Arsenic trioxide induces G_1-phase arrest and apoptosis, and thereby inhibits the growth of ATLL cell lines and of HTLV-1 infected T-cell lines, as well as induction of apoptosis in fresh ATLL cells derived from patients (Ishitsuka K. *et al.*, 1998; 2002). The adverse events of

arsenic trioxide *in vivo* are manageable and include mainly haematological, with some neurological toxicity.

The surface of ATLL cells characteristically express CD3, CD4, and CD25 (interleukin-2 receptor α). Therefore, these molecules, especially CD25 have been considered promising therapeutic targets as normal resting cells do not express CD25. Nineteen patients, with acute and chronic lymphoma, with or without prior chemotherapy were administered with murine anti-CD25 antibody, which blocks the interaction of IL-2 with high-affinity receptors but functions neither through complement-dependent cytotoxicity, nor through inducing antibody-dependent cellular cytotoxicity (Waldmann T.A. *et al.*, 1993). One patient each with acute and chronic type ATLL achieved complete remission, and partial remission was achieved in one with acute, two with lymphoma and one with chronic type ATLL. The response duration varied from 2 to more than 60 months. Interestingly, the clinical responses were not apparently associated with previous chemotherapy and magnitude of tumour burden. No significant adverse events developed except fever following administration. Serum levels of soluble CD25 (sCD25) are high in ATLL patients, but sCD25 in the circulation did not prevent anti-CD25 from reacting with and saturating its binding sites on ATLL cells. Recent reports have described the effects of a humanized anti-CD25 monoclonal antibody daclizumab (Osborne G.E. et al., 2006), an anti-CD25 antibody fused to the truncated Pseudomonas exotoxin LMB-2 (Kreitman R.J. *et al.*, 2000), and an interleukin-2 fused with amino acids from the diphtheria toxin denileukin (Di Venuti G. *et al.*, 2003). In particular this last work report a case of human T-cell lymphotropic virus 1 (HTLV-1)-associated adult T cell leukemia/lymphoma (ATLL) in clinical remission > 1 year after therapy with denileukin diftitox and hyper-CVAD (hyperfractionated cyclophosphamide/doxorubicin/vincristine/decadron). It suggested that denileukin diftitox may affect the paracrine secretion of HTLV-1-associated

clinical manifestations of ATLL. The frequent expression of CC chemokine receptor 4 (CCR4) on ATLL cells is suggested to be a promising target, and a clinical trial is currently underway in Japan against relapsed/refractory ATLL using the chimeric anti-CCR4 antibody KM2760, which exerts anti-ATLL activity mediated by antibody dependent cellular cytotoxicity (Yoshie O. *et al.*, 2002; Ishida T. *et al.*, 2004).

1.5.2 Treatment of HTLV-1-associated myelopathy/Tropical Spastic Paraparesis

There is no established therapy for TSP/HAM. Clinical improvements have been reported for a number of agents in open-label studies including corticosteroid, plasmapheresis, danazol (Harrington W.J. *et al.*, 1991), pentoxifylline (Shirabe S. *et al.*, 1997), and interferon. With the exception of interferon-α, however, these drugs lack the quality of evidence required to merit a strong recommendation for their use in HAM/TSP. The evidence for supporting the use of corticosteroids in this patients is based on uncontrolled case series (Osame M. *et al.*, 1987). The immunomodulatory effects of corticosteroids (Cupps T.R. *et al.*, 1982) are the rationale base for their use in HAM/TSP. To date, data describing the real benefit of corticosteroids use for treatment of TSP/HAM in the literature are limited. Partly, this is owe to the fact that few studies have had a longer follow-up time. In a recent study it has been evaluated the clinical corticosteroid effect on TSP/HAM in a long-term follow-up (Croda M.G. *et al.*, 2008). It has been studied 39 patients with HAM/TSP who received methyl-prednisolone treatment and after 10 years it has been observed a significant neurological improvement reaching 24,5% according to the Incapacity Status Scale (ISS) score. These results were similar to those from a study which evaluated 200 TSP/HAM patients, and in ten patients had 30% motor improvement after the use of methyl-prednisolone, and a 69% improvement among patients who used oral prednisolone and intrathecal hydrocortisone injection (Nakagawa M. *et al.*, 1996).

Although many questions remain regarding the usefulness of corticotseroids in HAM/TSP. Instead, interferon-α demonstrated clinical benefits for subjects with TSP/HAM in a blinded trial (Izumo S. et al., 1996). The main marker of efficacy during interferon-a therapy appears to be a reduction in HTLV-1 proviral load (Saito M. et al., 2004); the reduction in proviral load was associated with changes in CD8+ T cells. Following the modest success of interferon-α therapy in HAM/TSP, long-term treatment with interferon-β was tested in a cohort of 12 patients. No significant clinical changes were observed during the trial in this cohort; among the number of biomarkers measured, significant reduction in the frequency of Tax-specific CD8+ T cells was observed along with a reduction in HTLV-1 Tax mRNA load and the spontaneous lymphoproliferation. No significant changes were observed in the HTLV proviral load. These results suggested that interferon-β therapy had an overall immune-modulatory effect in HAM/TSP as evidenced by the relative suppression of spontaneous proliferation, and demonstrated that interferon-β therapy had a profound effect on virus-specific cellular immune responses (Oh U. and Jacobson S., 2008). Regarding antiretroviral therapy, initial observational studies suggested clinical benefit and reduction of HTLV-1 proviral load with therapy including zidovudine (Gout O. *et al.*, 1991; Sheremata W.A. *et al.*, 1993) and lamivudine (3TC, Taylor G.P. *et al.*, 1999). However *in vitro* studies which have demonstrated limited activity of 3TC against the HTLV-1 reverse transcriptase (Derse D. et al., 2001; Balestrieri E. et al., 2002), very likely due to a natural resistance of HTLV-1 reverse transcriptase to lamivudine (Toro C. *et al.*, 2003). On one side the poor ability of anti-retroviral agents to reduce HTLV-1 virus load *in vivo* in patients with HAM/TSP, might be due to the preferential HTLV-1 replication mechanism through the clonal expansion of infected cells rather than through the reverse transcriptase pathway (Machuca A. *et al.*, 2001; Taylor G.P. *et al.*, 2006).On the other it cannot be excluded that the antiretroviral drugs, directly

translated from the experience on HIV infection are not suitable to inhibit HTLV-1 infection.

To date, proinflammatory cytokines implicated in the pathogenesis of immunomediated inflammatory diseases represent rational targets for therapy. For example, IL15 is a proinflammatory cytokine that appears to be dysregulated in HAM/TSP, and may play a pathogenic role in this disease (McInnes I.B. and Gracie J.A., 2004). A phase I/II clinical trial is under way to test the safety and provide preliminary efficacy data of a monoclonal antibody, Hu MiK-β1, that blocks IL15 signalling.

Recent work in HIV suggest that histone deacetylase inhibitors such as valproic acid (VPA) may induce expression of HIV from previously quiescent HIV-infected CD4+ T cells (Ylisastigui L. *et al.*, 2004; Lehrman G. *et al.*, 2005), making the virus a target of antiretroviral therapy. A single-arm, open-labelled trial tested the benefit of VPA in 19 patients with HAM/TSP. Preliminary data suggest VPA administration induced a transient increase then a drop in HTLV-1 proviral loads in HAM/TSP patients (Lezin A. *et al.*, 2007). The authors hypothesized that VPA led to increased viral expression allowing subsequent destruction of the virus by the host immune response.

1.6 REVERSE TRANSCRIPTASE INHIBITORS

The reverse transcriptase (RT) of the viruses is a viral enzyme necessary for the catalytic formation of proviral DNA from viral RNA. This enzyme has been an active target for drug development for a number of years. Many inhibitors of viral RT which can be divided into two categories have been discovered. The first group consists of nucleoside reverse transcriptase inhibitors (NRTIs). These are competitive inhibitors, which act as DNA chain terminators. The others are the non-nucleoside reverse transcriptase inhibitors (NNRTIs). These are noncompetitive inhibitors and noncovalently bind at a site proximal but different from the site of the polymerase activity (Figure 5). Inhibitors of the latter class are particularly attractive drug candidates because their binding is highly specific to the reverse transcriptase, and therefore, they lead to less adverse side effects. A third group consist in protease inhibitors, which block the maturation of precursors of viral proteins and prevent the generation of mature viral proteins.

1.6.1 Nucleoside reverse transcriptase inhibitors (NRTIs)

NRTIs are structurally similar to the building blocks of nucleic acids (RNA, DNA) but differ from their natural analogues by the replacement of the hydroxy group in the 3′ position by another group that is unable to form the 5′ to 3′ phosphodiester linkage that is essential for DNA elongation (Stein D.S. and Moore K.H., 2001).

After the acyclic nucleoside analogues have been taken up by the cells, they have to be phosphorylated through three consecutive phosphorylation steps (Figure 6) before they can interact, in their triphosphate form, with their target enzyme, the viral DNA polymerase. Of crucial importance in this phosphorylation process is the first phosphorylation step which is ensured by a specific virus-encoded thymidine kinase (TK). Once that the compounds have been phosphorylated to the monophosphate, cellular kinases will afford

their further phosphorylation to the di- and triphosphate stages. In their triphosphate form, the compounds then interact as competitive inhibitors or alternate substrates with the normal substrates [2′-deoxynucleoside 5′-triphosphates (dNTPs)], and if they are incorporated into the DNA chain, they may act as chain terminators, thus preventing further chain elongation.

To work around this problem, have recently been synthesized compounds that have a phosphonate group instead of a phosphate group (ANPs, acyclic nucleoside phosphonates).

Figure 5: Mechanism of action of nucleoside and nucleotide analogues on reverse transcriptase. In figure is reported the activities of a NRTIs, the AZT, on a cellular DNA polymerase (a) and reverse transcriptase (b).

Figure 6: Mechanism of phosphorylation of nucleoside and nucleotide analogues: a) Zidovudine (AZT); b) Lamivudine (3TC); c) Tenofovir (PMPA); d) PCOAN.

Acyclic nucleoside phosphonates possess a phosphonate group attached to the acyclic nucleoside moiety through a stable P—C bond. In contrast to the phosphate group (which is attached through a P—O—C bond), a phosphonate group (P—C bound) cannot be cleaved off by cellular hydrolases (esterases). Foremost among the acyclic nucleoside phosphonates that have been pursued as antiviral agents are cidofovir (HPMPC) [(*S*)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine], adefovir (PMEA) [9-(2-phosphonylmethoxyethyl)adenine], and tenofovir (PMPA) [(*R*)-9-(2-phosphonylmethoxypropyl)adenine] (De Clercq E., 2003).

Since the acyclic nucleoside phosphonates already contain a phosphate-mimetic group, stably attached through a P—C bond, they need only two, instead of three, phosphorylation steps to reach the active metabolite stage (De Clercq E. and Holy A., 2005). Thus, acyclic nucleoside phosphonates do not depend on the virus-induced kinase to exert their antiviral action, and, in "bypassing" the nucleoside kinase step, the acyclic nucleoside phosphonates may be expected to act against a broad range of DNA viruses, including hepadnaviruses (hepatitis B virus [HBV]) and retroviruses (human immunodeficiency virus [HIV]), i.e., all the viruses that use for their replication a DNA polymerase through which the active metabolites of the acyclic nucleoside phosphonates could enter into competition with the normal substrates (dNTPs).

1.6.2 Main nucleoside and nucleotide inhibitors used in therapy

1.6.2.1 Zidovudine

Zidovudine (3'-azido-3'-deoxythymidine, AZT) is an analogue of thymidine (Figure 7a) in which the 3'-hydroxyl group is replaced by an azido group. It is know that this compound is intracellularly phosphorylated by nucleoside and nucleotide kinase to its 5'-triphosphate, and that in this form inhibits retroviral reverse transcriptase.

The AZT remains the most common agent prescribed in the treatment of HIV infection, but it, combined with interferon-α, has been suggested as a first line treatment for ATLL. The mechanism of the anti-ATLL effects induced by AZT and interferon-α therapy have not been defined. Intracellular phosphorylation changes AZT into its active form (zidovudine triphosphate; ZDV-TP), which is incorporated into viral DNA and then reverse transcriptase is inhibited via DNA chain termination (Furman P.A. *et al.*, 1986). However, ZDV-TP is reported to be incorporated into cellular DNA *in vitro*, its ability to inhibit cellular polymerases α and γ is 100-fold less potent than that to inhibit HIV reverse transcriptase (Copeland W.C. *et al.*, 1992). Therefore, ZDV-TP probably does not directly affect cellular DNA. In fact, neither AZT nor interferon-α has direct toxicity against ATLL cell lines and against fresh ATLL cells obtained from patients who achieved complete remission after AZT and interferon-α therapy (Bazarbachi A. *et al.*, 2000).

1.6.2.2 Lamivudine

Lamivudine (3TC), the negative enantiomer of 2'-deoxy-3'-thiacytidine (Figure 7b), is a dideoxynucleoside analogue used in combination with other agents in the treatment of human immunodeficiency virus type 1 (HIV-1) infection and as monotherapy in the treatment of hepatitis B virus (HBV) infection (Chang C.N. *et al.*, 1992). Lamivudine undergoes anabolic phosphorylation by intracellular kinases to form lamivudine 5'-

triphosphate, the active anabolite that prevents viral replication by competitively inhibiting viral reverse transcriptase and terminating proviral DNA chain extension. The pharmacokinetics of lamivudine are similar in patients with HIV-1 or HBV infection, and in healthy volunteers. The drug is rapidly absorbed after oral administration, with maximum serum concentrations usually attained 0.5 to 1.5 hours after administration (Palumbo E., 2008).

Clinical investigations suggested that thia-2'-3'-dideoxycytidine (lamivudine; 3TC) could also be, at least partially, efficacious in the treatment of HAM/TSP or ATLL (Machuca A. and Soriano V., 2000; Taylor G.P. *et al.*, 1999). However, *in vitro* studies have cleared up some misconceptions about using lamivudine in HTLV-1-infected individuals. In fact, we showed that lamivudine completely inhibited HTLV-1 infection of PBMC *in vitro* only at concentrations considered out of the range of those used in antiviral therapy (Macchi B. *et al.*, 2003; Balestrieri E. *et al.*, 2002).

1.6.2.3 Tenofovir

The tenofovir disoproxil fumarate (TDF or bis (POC) PMEA) is a prodrug, of nucleotide tenofovir (TFV or PMPA) (Figure 8a). This is a nucleotide analogues of adenosine 5'-monophosphate, and has some efficacy against HIV RT (Cundy K.C. *et al.*, 1998). The TDF was synthesized to increase the absorption of oral drug and to improve its cellular uptake (Robbins B.L. *et al.*, 1998). After oral administration, the TDF is rapidly hydrolyzed *in vivo* in tenofovir, which is phosphorylated by cellular kinases in pharmacologically active metabolite called diphosphate tenofovir (Robbins B.L. *et al.*, 1998). The PMPA owe its selective antiviral activity to the fact that in its diphosphorylated form, it has a higher affinity for the viral DNA polymerase than for cellular DNA polymerases α, β, γ, δ and ε. The PMPApp interact as competitive or alternate substrate

with the natural nucleotide deoxyadenosine 5'-triphosphate (ATP) for the viral DNA polymerase. The incorporation of one molecule of PMPA at the 3' end of the growing DNA chain suffices to terminate further chain elongation (De Clercq E., 2003).

The comparison with the other NRTIs currently used for treatment of HIV infection indicates that within the class of NRTIs, the potential that tenofovir will produce adverse effects caused by drug-associated mitochondrial dysfunction is low (Birkus G. *et al.*, 2002, Lee H. *et al.*, 2003).

Zidovudine (AZT)

Lamivudine (3TC)

Figure 7: Chemical structure of nucleoside analogues: a) Zidovudine (AZT) and b) Lamivudine (3TC).

Tenofovir (TFV)

	PCOAN3	PCOAN2	PCOAN1
B			

Figure 8: Chemical structure of nucleotide analogues: a) Tenofovir (TFV) and b) phosphonated carbocyclic compounds of which shows the nitrogenous bases that distinguish the different PCOANs.

1.6.3 Non-nucleoside reverse transcriptase inhibitors (NNRTIs)

The nonnucleoside reverse transcriptase inhibitors (NNRTIs) are a structurally and chemically dissimilar group of antiretrovirals that are potent and highly selective inhibitors of HIV reverse transcriptase. Other retroviral reverse transcriptase enzymes, such as HIV-2, hepatitis viruses, herpes viruses, and mammalian enzyme systems, are unaffected by these compounds. Unlike the nucleoside analogs, the NNRTIs interfere with reverse transcriptase by noncompetitively binding directly to the enzyme downstream from the active catalytic site (Grob P.M. *et al.*, 1992). The compounds are active in their native state, requiring no phosphorylation or other activity-dependent alteration. They are extensively metabolized in the liver; very little drug is excreted unchanged (Murphy R. and Montaner J., 1996).

The NNRTIs are potent antiretroviral agents that can successfully be used in appropriate triple-therapy regimens. The two main advantages of initiating therapy with an NNRTI-containing regimen are the ability to delay the use of protease inhibitors and the favourable adherence properties of NNRTIs, such as once-daily dosing. NNRTI performance in patients with advanced HIV disease has not been as impressive as that achieved with the protease inhibitors, but this may be due to suboptimal study design. Unfortunately, resistance to the NNRTIs can develop rapidly, often following a single mutation. This is particularly true if they are used as monotherapy or are added to a failing or suboptimal regimen of nucleoside analogs. Although structurally dissimilar to each other, all NNRTIs bind the reverse transcriptase enzyme in the same binding pocket. Nevirapine, efavirenz and delavirdine drugs are representative of this class.

Similarly, drugs that induce or inhibit the activity of cytochrome can have an effect on plasma concentrations of NNRTIs. The most common adverse drug reaction of NNRTIs, is the rash, observed in 35% of patients who received nevirapine (Ananworanich J. *et al.*,

2005). Nevirapine is also linked to serious liver toxicity (Nunez M. *et al.*, 2001). Efavirenz is associated with the development of disturbances in the CNS (such as dizziness, hallucinations, insomnia) and fetal malformations, when administered to pregnant women (De Santis M. *et al.*, 2002). Furthermore both nevirapine and efavirenz are associated with dyslipidemia.

1.6.5 Experimental evaluation of activity of reverse transcriptase

RT is a retroviral RNA-dependent DNA polymerase essential for retrovirus replication. Assay for RT activity are usually based on its enzymatic capacity to synthesise DNA from RNA templates. Traditional systems have relied upon incorporation of radiolabelled nucleotides for monitoring cDNA synthesis by using synthetic homopolymeric template-primers such as poly(rA)-oligo(dT) or poly(rC)-oligo(dG) (Neumuller M. *et al.*, 1990; Lee M.H. *et al.*, 1987). Methodological developments to improve sensitivity have included the use of non isotopic material (Urabe T. *et al.*, 1992; Eberle J. *et al.*, 1992). Afterwards, several PCR-based detection RT assays, called PERT (Product-Enhanced Reverse Transcriptase), have been described where RT reaction is performed on an RNA template such as the RNA from Brome Mosaic Virus or bacteriophage MS2 (Silver J. *et al.*, 1993; Pyra H. *et al.*, 1994). Actually PERT assay is a PCR-based RT assay that involves three steps: reverse transcription, amplification by PCR and detection of PCR products by ELISA. These PCR-based assays are several orders more sensitive than incorporation-based ones for the detection of RT activity.

Another ultrasensitive tests to evaluate RT activity is the Amp-RT assay, it utilizes a known heteropolymeric RNA template and a complementary DNA oligoprimer. The reverse-transcribed cDNA is detected by PCR amplification and Southern-blot hybridization (Yamamoto S. *et al.*, 1996). The comparative analysis of seven retroviruses

with Amp-RT and the three conventional RT assays showed that Amp-RT was a generic with unprecedented sensitivity on both lentiviruses and oncoviruses. The high sensitivity of Amp-RT obviates the need for virus concentration which has complicated the detection of many oncoviruses by the conventional RT assays. Amp-RT was also found to be 100 and 10000 times more sensitive than antigen capture assays for HTLV-1 and HIV, respectively.

2. AIM OF STUDY

Clinical and experimental data on HTLV-1 infection have provided only partial answers that do not permit yet to define a protocol of treatment for these diseases. However, encouraging results have been obtained through the use of *in vivo* experimental combination of IFN-α and AZT in ATLL patients. In addition, some data from experimental procedures performed *in vitro* suggest the need for further studies aimed at identifying new compounds that can control the HTLV-1 life cycle. In particular the experience on HIV infection emphasized as phosphonates compounds (of which one example currently used in clinical is tenofovir) are able to check HIV infection. Data in other and our laboratory have revealed that tenofovir is active in blocking *in vitro* infection with HTLV-1 in different experimental models (Hill S.A. *et al.*, 2003; Balestrieri E. *et al.*, 2005). These findings prompted us on one hand, to further expand the study on new molecules endowed with RT inhibitory activity, on the others to develop more specific methods to test the inhibitory effect of new molecules on reverse transcriptase activity directly in patients. In line with these attempts, in a more recent work, we have shown the effects of a newly synthesized family of phosphonated nucleoside compounds, phosphonated carbocyclic 2′-oxa-3′-aza-nucleosides (PCOANs), on HTLV-1 infection *in vitro* (Chiacchio U. *et al.*, 2005; Balestrieri *et al.*, 2008). To ascertain the anti-HTLV-1 activity of PCOANs, peripheral blood mononuclear cells from healthy donors were infected *in vitro* by co-culture with an HTLV-1 donor cell line in the presence of three prototype PCOAN compounds. PCOANs were able to completely inhibit HTLV-1 infection *in vitro* at a concentration of 1 μM, similar to what has been observed for tenofovir and azidothymidine. The mechanisms involved in the anti-HTLV-1 effects of PCOANs can mainly be ascribed to their capacity to inhibit HTLV-1 reverse transcriptase activity, as ascertained by means of a cell-free assay. Overall, these results indicate that the

family of PCOANs includes potential candidate compounds for long-lasting control of HTLV-1 infection. However, no information is available at the moment on the effects of potential anti-HTLV-1 anti-retroviral agents on RT activity in clinical isolates from HTLV-1 infected patients.

The principal aim of this study was to investigate: 1) the detectability of HTLV-1 RT activity in stimulated mononuclear cells from TSP/HAM and or ATLL HTLV-1-infected patients in comparison with chronically HTLV-1 infected cell lines, 2) the effects of RT inhibitors *in vitro* on reverse transcriptase activity from patients with TSP/HAM and/or ATLL, enrolled in different therapeutic protocol in comparison with those from chronically HTLV-1 infected cell lines.

3. MATERIALS AND METHODS

3.1 Characteristics of patients and sample collection

The patients enrolled in the study belong to two groups, represented by patients with HAM/TSP, or with ATLL diseases. Within these two groups are included both patients without therapy and a cohort of patients both pre- and post- therapy. The time of enrollment and the type of therapy are listed in the Table 3 and Table 4. In addition HAM/TSP patients failing AZT/Lamivudine protocol were enrolled in a therapy protocol encompassing treatment with TDF. PBMCs from heparinized blood of patients with HAM/TSP or ATLL were separated by Ficoll/Hypaque density gradient (Pharmacia Uppsala, Sweden), according the manufacture's instructions, and then washed three times in phosphate buffered saline (PBS). To utilize virus isolates from patients as a source of RT for the subsequent assay, paired samples of PBMC from patients of different cohort were cultured at a concentration of 0.8×10^6/ml in RPMI plus 15% FBS in the presence of 20 U/ml of IL-2, for at least 1 week before harvesting the supernatants. To quantify released virus in the culture medium, harvested supernatants were cleared at 1,000 g, filtered on 0,45μm and then ultracentrifuged at 30,000 g for 4 hr at 4°C (Beckman 45 TI). The presence of HTLV-1 p19 viral protein was detected in the viral lysates using a commercially available antigen capture ELISA (Retro-tek p19 antigen ELISA, Zeptometrix, Buffalo, New York). In comparison MT2 and chronic infected cells supernatants, were centrifuged and viral lysate assessed for p19 were used in the assays as positive control. The assays were performed according to the manufacturer's protocols.

3.2 Cell lines and infection of PBMCs

Peripheral blood mononuclear cells (PBMCs) were harvested from healthy adult donors,

who were seronegative for HIV and B/C hepatitis viruses. Mononuclear cells were separated by Ficoll/Hypaque density gradient (Cederlane, Hornby, Ontario). The cells were then washed twice in RPMI-1640 medium (Gibco-Invitrogen Co., Paisley, Scotland UK). HTLV-1 infection was performed by co-culturing PBMCs with lethally irradiated (120 Cy, from a caesium gamma cell irradiator 1000, Canada Atomic Energy Ltd., Canada) MT-2 (irrMT-2) cells at a ratio of 5 PBMCs to 1 virus-donor cell. MT-2 is chronically HTLV-1-infected cell lines, derived from cord blood mononuclear cells exposed to HTLV-1 from leukemic patients**.** PBMC/irrMT-2 co-cultures were maintained at 0.8×10^6 cells/ml in RPMI-1640 medium (Gibco) supplemented with 12% FBS, glutamine, penicillin-streptomycin (Gibco-Invitrogen; hereinafter referred as complete medium, CM) and 20 U/ml of recombinant interleukin 2 (IL-2; PROLEUKIN, Chiron Co., Holland).

In addition supernatant from few chronically infected cell lines was tested in the RT inhibitory assay. These cell lines have been generated either through limiting dilution of in toto PBMC infected with irradiated MT-2 donor cell line and from CD4+ and/or CD8+ T lymphocytes separated through immunomagnetic beads, and then infected by co-culture with irradiated MT-2 cells. The characteristics of these HTLV-1 chronic infected cells were listed in the Table 3.

Group	Sample Code	Disease	Pre-therapy Date	Post-therapy Date	Therapy
1	*HAM/TSP #2*	HAM/TSP		——	[a]NT
	HAM/TSP #3	HAM/TSP		——	NT
	HAM/TSP #4	HAM/TSP		——	NT
	HAM/TSP #5	HAM/TSP		——	NT
2	*TSP #6 (F64807)*	HAM/TSP	08/11/1999	09/10/2000	AZT-3TC
	TSP #7 (F65074)	HAM/TSP	22/11/1999	20/11/2000	AZT-3TC
	TSP #8 (M68847)	HAM/TSP	17/04/2000	30/04/2001	AZT-3TC
	TSP #9 (M81087)	HAM/TSP	22/05/2000	21/05/2001	AZT-3TC
	TSP #10 (F84219)	HAM/TSP	17/08/2000	23/07/2001	AZT-3TC
	TSP #11 (M66441)	HAM/TSP	04/09/2000	13/08/2001	AZT-3TC

Table 3: Characteristics of TSP/HAM patients. [a]NT: not treated.

Group	Sample Code	Disease	Pre-therapy Date	Post-therapy Date	Therapy
	ATLL-1	ATLL	2002	2004	AZT-IFN
	ATLL-2	ATLL	2000	2001	AZT-IFN
	ATLL-3	ATLL	——	——	NT
	ATLL-4	ATLL	——	——	NT
3	*ATLL-5*	ATLL	——	——	NT
	ATLL-6	ATLL	——	——	NT
	ATLL-7	ATLL	2000	2001	AZT-IFN
	ATLL-8	ATLL	2002	2003	AZT-IFN
	ATLL-9	ATLL	2002	2003	AZT-IFN

Table 4: Characteristics of ATLL patients. [a]NT: not treated.

Sample Code	weeks in colture	IL-2 dependent
CD4/MT2	6	+
CD4/MT2	14	+
B7(CD4/MT2)	44	+
CD8/MT2	14	+
PBMC/MT2	24	+
MT2	——	-

Table 5: Characteristics of chronic infected cell lines.

3.3 Assayed compounds

Three licensed reverse transcriptase inhibitors, zidovudine (AZT), lamivudine (3TC) and tenofovir (TVF) and three experimental prototype compounds PCOANs referred to as, PCOAN1, PCOAN2 and PCOAN3 were used. The acyclic phosphonate tenofovir (kindly provided by Dr. Jan Balzarini, Rega Institute for Medical Research, Leuven, Belgium) and the NRTI AZT (Wellcome Research Laboratories, Beckenham, England, UK), were used as reference compounds. The PCOANs are a family of newly synthesized compounds which belong to a group of cyclic nucleoside phosphonates, with the furanose ring replaced by an N,O-heterocyclic ring (Chiacchio U. *et al.*, 2003-2007). PCOANs were dissolved in DMSO and maintained at stock concentrations of 200 mM at −20 °C. Tenofovir and AZT were dissolved in culture medium without serum and maintained at stock concentrations of 100 mM at −20 °C. The compounds were diluted in culture medium without serum at concentrations appropriate to obtain the final usage concentrations just prior to their use.

3.4 RNA extraction

RNA isolation was performed using Nucleo Spin RNA kit and, to remove possible DNA contamination, RNA was treated with RNase free Dnase, aaccording to the manufacturer's instructions (Machenery-Nagel, Dueren, Germany). The quantity and the quality of all RNA preparations were assessed by gel electrophoresis and OD_{260}/OD_{280} ratios.

3.5 Genomic DNA extraction and *pol* region amplification

At 4 weeks p.i., cells from cultures were harvested and centrifuged on a density gradient to eliminate debris and dead cells. Cells were then incubated with proteinase K at 37°C for two hours, and DNA was extracted in phenol-chloroform-isoamylalcohol, according to

standard procedures. Five hundred nanograms of DNA was used as a template and amplified in a standard PCR mixture: 1× PCR buffer, a 0.2 mM concentration of each deoxynucleoside triphosphate (dNTP), 0.5 μM primer pair specific for the *pol* region of HTLV-1 (forward primer, 5′-CTGTCACAGAACTGCCGCAG-3′; reverse primer, 5′-AGCAGCAGTGGCCACTTG-3′) (Perkin Elmer, Boston, MA), and 1.25 U of *Taq* Gold polymerase (Promega, Madison, WI). As an internal control, the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was amplified using the same PCR mixture with a specific primer pair (forward primer, 5′-CCATGGAAAAAGGCTGGGG-3′; reverse primer, 5′-CAAAGTTGTCATGGATGACC-3′). Samples were subjected to 30 cycles of PCR amplification, each cycle consisting of 30 s at 94°C, 30 s at 55°C, and 45 s at 72°C on a DNA thermal cycler (Eppendorf, Hamburg, Germany). Following the final cycle, samples were incubated at 72°C for 7 min to ensure the completion of the final extension step.

3.6 RT inhibition assay

To test the sensitivity of HTLV-1 isolates from patients to RT inhibitors we set up a novel *ex vivo*, cell-free HTLV-1-RT inhibition assay. This assay is a modified version of a method we have described and utilized to screen the HTLV-1-RT-inhibitory activity of antiretroviral compounds in vitro (Chiacchio U. *et al.*, 2005; Balestrieri E. *et al.*, 2005-2008). The modification essentially consists of usage of isolates from patients as source of HTLV-1 RT in place of viral lysates from HTLV-1 chronically infected cell lines. As a template for reverse transcription, RNA was extracted from transfected cells ectopically expressing the glycoprotein D (gD) of herpes simplex virus type (Medici M.A. *et al.*, 2003) and treated with RNase free DNase (see Figure 9). Compounds to which sensitivity was assayed were activated through pre-incubation with a crude extract, prepared from

phytohaemagglutinin (PHA) and interleukin-2 (IL-2) stimulated PBMCs from healthy, HIV/HBV/HCV negative donors. For preparation of the crude extract, $1x10^6$ PBMCs, previously stimulated with PHA 2 μg/ml and IL-2 20 U/ml, for 72h in RPMI plus 20% FCS, were lysed in a buffer (50 mM Tris-HCl pH 7.4, 1 mM EDTA, 1 mM EGTA pH 7.4, 0.05% Triton-X, 150 mM NaCl, 0.25% sodium deoxycholate, 0.1% NP-40 and, freshly added, 1 mM PMSF, 15 μM DTT, 5 μg/ml leupeptin, 5 μg/ml pepstatin, 5 μg/ml aprotinin, 1 mM Na_3VO_4, 20 mM Na_3F, all from Sigma) on ice and centrifuged at 10000g. Lysed extracts (Figure 9) were incubated with the compounds at different concentrations for 15 minutes on ice and for successive 45 minutes at 30°C and then for 5 minutes at 95ºC to inactive the mixture. As a source of HTLV-1 RT *ex vivo*, amounts of viral lysates from different isolates obtained from HTLV-1 chronically infected cells, HAM and ATLL patient samples equivalent to 20 pg of p19 were utilized to obtain HTLV-1 RT preparations for each RT-PCR reaction. Total DNase-treated RNA (0,5 μg) was specifically reverse transcribed using 0.5 μM reverse primer specific for the gD gene U_S6 (5' TGTCGTCATAGTGGGCCTCCAT 3') in a reaction mix containing 1X RT buffer, 100U RNase inhibitor, 1 mM dNTP, 10 mM DTT, (all from Promega, Madison, WI) plus HTLV-1-RT preparations from patients in a volume of 10 μl. The reactions were performed in the presence or absence of activated substances, for 1h at 37 ºC. To investigate the dose-response, the assayed compounds, AZT, lamivudine, tenofovir and PCOAN1, PCOAN2, PCOAN3 were added at different concentrations. After incubation at 95 ºC for 5 minutes, 5 μl of RT reaction were used for DNA PCR in a reaction mix containing 1X Taq Gold buffer (Promega), 0.5 μM primer pair (U_S6 reverse, see above, and U_S6 forward, 5' AGACTTGTTGTAGGAGCATTCG 3'), 0.2 mM dNTP, 5 mM $MgCl_2$, 1.25 U Taq Gold Polymerase (Promega) performed for 20 cycles. Amplified DNA

(350 bp) was visualised on a 2% agarose gel containing ethidium bromide. Inhibition of HTLV-1 RT preparations from cultured MT-2 cells was used as a control.

3.7 Detection of p19 through antigen capture assay

Supernatants from infected cultures, or from MT-2 cell line were assayed for production of HTLV-1 p19 using an HTLV-1 p19 Gag antigen capture enzyme-linked immunosorbent assay (ELISA) purchased from ZeptoMetrix (Buffalo, NY). The assays were performed according to the manufacturer's protocols.

Figure 9: Restriction map of the plasmid pCJ3 in which it has been placed the gD fragment (indicated by red arrow) encoding the glycoprotein D of Herpes Simplex virus 1.

Figure 10: Schematic design of Reverse Transcriptase inhibition assay.

3.8 Real Time quantitative Reverse Transcription PCR

Real Time quantitative Reverse Transcription PCR (qRT-PCR) was performed on a Biorad instrument (IQ5) with gene-specific primers and the SybrGreen chemistry to evaluate the *pol* expression (forward primer, 5′-CTGTCACAGAACTGCCGCAG-3′; reverse primer, 5′-GCTGACCCTCACTGGCACC-3′) in the ATLL cohort of patients. All primers employed were cDNA specific and were purchased from Invitrogen (Carlsbad, CA). An amount of 0.25 micrograms of total RNA from each sample was reverse-transcribed in a total volume of 20 µl with high-capacity cDNA Reverse Transcription Kits (Applied Biosystems), according to the manufacturer's instructions.

Amplification of specific PCR products was detected using the SYBR Green PCR Real Master Mix (Eppendorf). The qRT-PCR was performed in triplicate in a total reaction volume of 25 µL containing 11,25 µL SYBR Green PCR Master Mix, 150 nM forward and reverse primers and 150 ng cDNA as a template. Samples were heated for 10 min at 95ºC and were subjected to 40 cycles of PCR amplification, each cycle consisting of 15 s at 95ºC and 60 s at 60ºC. Within each experiment, no template control (NTC) and housekeeping genes (GUSB, glucoronidase), used as reference, were run in parallel to verify any contamination and to determine amplification efficiency. Each run was completed with a melting curve analysis to confirm the specificity of amplification and lack of unspecific products and primer dimmers. Quantification was performed using the Ct comparative method. Relative gene mRNA levels were calculated as follows: $2^{-[\Delta C_t (sample) - \Delta C_t (calibrator)]} = 2^{-\Delta\Delta C_t}$, where $\Delta C_t (sample) = [C_t(\text{gene target}) - C_t(\text{GUSB})]$ represents the difference, in threshold cycle number, between genes and GUSB.

3.9 Determination of cytotoxicity of the compounds.

Inhibition of cell metabolic activity revealed by reduction of the oxidative burst was detected through formazan product formation, using a commercial colorimetric kit (MTS [3,4-(5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy phenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt]) (Cell Titer 96 Aqueous One Solution; Promega). The assay was performed by seeding 1×10^4 MOLT-3 cells in 100 μl in the presence or absence of PCOANs or the reference compounds at seven different concentrations ranging from 10 nM to 1 mM in RPMI medium supplemented with 5% FBS, glutamine, and penicillin-streptomycin. Twenty microliters of Cell Titer 96 Aqueous One Solution reagent was added directly to culture wells at the end of the culture period and incubated for 1 to 4 h. Reaction was stopped adding SDS and then, absorbance was read at 490 nm.

4. RESULTS

4.1 Optimization of *cell-free* RT assay and effect of PCOANs on HTLV-1 RT activity from the MT-2 cell line.

Having demonstrated that PCOANs were able to exert an anti-HTLV-1 antiviral effect *in vitro* which was at least comparable with that of TFV and AZT, it was interesting to obtain further information about their mechanism of action (Balestrieri *et al.*, 2008). In fact, based on their structure, the potential target of PCOANs would appear to be reverse transcription of the virus by the HTLV-1-specific RT enzyme. To directly test this hypothesis, a cell-free RT inhibition assay, recently developed in the laboratory where this study has been carried out, was optimized. For the general study, viral lysate prepared from the MT-2 supernatant was used as a source of HTLV-1 RT. The tested compounds were first activated through incubation with a cell extract from mitogen-stimulated PBMCs as a kinase source. To obtain information on the phosphorylation efficiency of the adopted system, we compared the inhibitory effect of AZT activated through incubation with the cell extract from mitogen-stimulated PBMCs with that of a commercially available triphosphate-AZT. The inhibitory activity toward HTLV-1 RT of AZT subjected to PBMC extract activation was about 10 times lower than that of an equal quantity of triphosphate-AZT (data not shown). Figure 11A shows a series of control samples used in order to validate the assay. First, it was demonstrated that preincubation with the cell-free crude extract from mitogen-stimulated PBMCs did not affect cDNA formation and detection (Fig. 11A, lanes 1 and 2). In addition, as expected, subtraction of template RNA (lane 3), the primer pair (lane 4), or HTLV-1 RT (lane 5) prevented cDNA generation, as shown by the absence of the amplified product. Moreover, as a negative control, the activity of adefovir (ADF), a nucleoside compound lacking the hydroxymethyl group in the furanose ring (Chiacchio U. *et al.*, 2003) and consequently unable to act as an RT inhibitor chain

terminator, was assayed. In fact, (5′*S*)-5-fluoro-1-isoxazolidin-5-yl-1H-pyrimidine-2,4-dione was completely unable to inhibit cDNA generation either at 100 nM without crude extract activation (Fig. 11A, lane 6) or at 100 or 10 nM following crude extract activation (Fig. 11A, lanes 7 and 8). To investigate in detail the dose response of HTLV-1 RT inhibition for each compound, concentrations ranging from 1 to 0.1 nM following crude extract activation, based on previous experience with TFV and AZT and preliminary experiments with PCOANs, were used. Preactivated PCOAN1 and PCOAN2 at 1 and 0.8 nM inhibited cDNA elongation completely (Fig. 11B and C, lanes 2 and 3), while at concentrations ranging from 0.6 nM to 0.1 nM (Fig. 11B and C, lanes 4 to 7), neither was inhibitory. PCOAN3 completely inhibited cDNA generation at 1, 0.8, and 0.6 nM (Fig. 11D, lanes 2 to 4), while it did not exert any effect at lower concentrations (lanes 5 to 7). Both activated TFV and AZT inhibited cDNA at concentrations of 1, 0.8, 0.6, and 0.4 nM (Fig. 11E and F, lanes 2 to 5), while they were not effective at 0.2 and 0.1 nM (lanes 6 and 7).

A

	M	1	2	3	4	5	6	7	8
- Crude extract		+	-	+	+	+	-	+	+
- RNA		+	+	-	+	+	+	+	+
- Primer		+	+	+	-	+	+	+	+
- HTLV-1 RT		+	+	+	+	-	+	+	+

ADF (nM)

B

- Crude extract   - + + + + + + +

PCOAN1 (nM)

C

- Crude extract   - + + + + + + +

PCOAN2 (nM)

D

- Crude extract   - + + + + + + +

PCOAN3 (nM)

E

- Crude extract   - + + + + + + +

TFV (nM)

F

- Crude extract   - + + + + + + +

AZT (nM)

Figure 11: Effect of PCOANs on HTLV-1 RT activity.

4.2 Sensitivity of HTLV-1 isolates from chronically infected cells to RT inhibitors.

Having demonstrated that PCOANs are able to inhibit the enzymatic activity of HTLV-1 from the MT-2 cell line, the effect of these compounds on the RT activity from chronic infected cells listed Table 5, was investigated. To this purpose, the inhibitory concentrations of the six compounds, versus the supernatants of chronically infected cells through a dose-response assay using different range concentrations for each drugs (AZT 10-100 nM; 3TC 100-1000 nM; TVF, PCOAN-1, 2, 3, 1-10 nM) at low cycles of amplification (Table 6), were evaluated. The inhibitory effect of each drug tested is expressed in Table 6 as minimum inhibitory concentration 100 % (MIC_{100}) of RT activity. HTLV-1 RT from these supernatants was inhibited by AZT at concentrations of 2 − 8 nM which was less than the inhibitory concentration of HTLV-1 RT obtained from MT-2 cells. In two out of five HTLV-1 chronically infected cells the inhibitory concentration of lamivudine was $>10^3$ nM, while in the other cell lines the inhibitory concentration of lamivudine was 1000 nM. HTLV-1 RT from MT-2 cells was susceptible to tenofovir at 1 nM concentration, but concentrations from 6 to 8 nM were required to inhibit RT from B7 and PBMCs/MT2 6 months p.i.. The three unlicensed compounds, PCOAN-1, PCOAN-2 and PCOAN-3, all inhibited MT-2 HTLV-1 RT at 8 nM and also inhibited HTLV-1 RT from the infected cells at 2 − 8 nM concentration, with PCOAN3 being the most potent.

Cell Lines	MIC$_{100}$[a] (nM)					
	AZT	3TC	TVF	PCOAN1	PCOAN2	PCOAN3
CD4+/MT2 6w p.i.	8	1000	1	6	4	2
CD4+/MT2 14w p.i.	6	1000	1	8	6	4
B7 (CD4/MT2)	6	>1000	8	6	2	2
CD8+/MT2 14w p.i.	2	1000	1	4	8	4
PBMCs/MT2 6m p.i.	6	>1000	6	2	8	2
MT2	10	1000	1	8	8	6

Table 6: Susceptibility to NRTI of HTLV-1 RT from *in vitro* infected PBMCs cultures.

[a]MIC$_{100}$: Minimum Inhibitory Concentration able to inhibit 100% RT activity

4.3 Reverse transcriptase activity in the supernatant of PBMC cultures from patients with HAM/TSP.

Before testing the *in vitro* inhibitory activity of the different compounds on HTLV-1 RT from patients, the RT activity needed to generate cDNA from a known RNA template was assessed for all the samples, both from cultures of cells from the patients with HAM/TSP before and after therapy as well as from the MT-2 cell line. HTLV-1 p19 in the supernatants of the cultured PBMCs was quantified as a surrogate measure of the amount of RT. Serial dilutions of supernatant corresponding to 5 to 30 pg p19 were used to generate cDNA from the RNA template of gD transfected cells. The 350bp DNA-PCR amplified product from cDNA was quantitatively assessed by densitometry analysis after 2% agarose gel electrophoresis. Figure 12 and 13 showed that the amount of amplified product, for the first and second cohort of patients respectively, reached a plateau in the presence of an amount of p19 between 20 pg and 30 picograms. Therefore, supernatants containing the equivalent of 20 pg p19 were used in the RT inhibition assay. These results also indicated that the assay was sensitive enough to measure RT activity in the cultures from HTLV-1 infected patients. Furthermore the RT activity of the supernatants of stimulated PBMCs from patients with HAM/TSP, before and after therapy, overlapped with that of supernatants from the chronically infected MT-2 cell line.

Figure 12: Dose response of RT activity in HTLV-1 infected cultures. Supernatants of cultures from PBMCs for first cohort of patients with HAM/TSP (#2, #3, #4 and #5) and from MT-2 cells were assayed for p19 production.

Figure 13: Dose response of RT activity in HTLV-1 infected cultures. Supernatants of cultures from PBMCs of HAM/TSP patients undergoing therapy before (T0) and after (T48) therapy (TSP #6, TSP #7, TSP #8, TSP #9, TSP #10) and from MT-2 cells were assayed for p19 production. The HAM/TSP patient 11 was tested only before therapy.

4.4 Sensitivity of HTLV-1 isolates from HAM/TSP patients to RT inhibitors.

The susceptibility to NRTIs and NNRTI of HTLV-1 RT from four untreated HAM/TSP patients and from a cohort of six HAM/TSP patients that had participated in a randomised, double blind, placebo controlled study of AZT plus lamivudine, was evaluated.

The minimum inhibitory concentrations (MIC_{100}) of the six compounds for the first group of TSP patients and from the cohort of six patients under therapy are presented in the tables 7 and 8 respectively. In this serious of experiments drug concentration from 1 to 1000 mM were used. Regarding the first group of patients (Table 7), the HTLV-1 RT was inhibited by AZT at concentrations of 10 – 100 nM that was ten times more than the inhibitory concentration obtained from MT-2 cells (Table 6). Instead the inhibitory concentration of lamivudine and tenofovir was $>10^3$nM for all the four TSP/HAM isolates. The three phosphonate compounds all inhibited HTLV-1 RT from the same primary isolates at 10 – 1000nM concentration. The Figure 14 shows the *cell-free* RT assay image on the effect of NRTIs on HTLV-1 RT activity in PBMC of HAM/TSP patient # 4, as representative experiment. In Table 8 are shown the results of RT inhibitory assay of each drug at different concentration range (PCOANs and AZT: 1-10nM ; TVF and 3TC: 10-1000 nM; NEV: 50, 75, 100nM). The assay was performed at low cycles of amplification on samples from the cohort of both untreated and treated patients. The HTLV-1 RT from patients was inhibited by AZT at concentrations of 4 – 8 nM which was ten times less than that inhibiting of HTLV-1 RT of MT-2 cells. In five out of six patients and in MT-2 cells the inhibitory concentration of lamivudine was $>10^3$nM. Conversely, in one patient, before treatment, the inhibitory concentration of lamivudine was 400nM. The HTLV 1 RT from the primary isolates were inhibited by TVF at 10 nM. Interestingly, patient TSP #11, either before and after therapy, was more resistant, since its RT was inhibited by TFV at 1000 nM. The three unlicensed compounds, PCOANs; all inhibited RT from the TSP/HAM

primary isolates at 2 – 10nM concentration, with PCOAN1 being the most potent. Although PCOAN were phosphonates similarly to TFV they were more potent in inhibiting RTs from TSP patients. However, no main change in the sensitivity to inhibitory concentration of any RT inhibitor was seen in the primary isolates obtained from patients after 6 to 12 months therapy with AZT plus lamivudine. Only for this cohort of patients, also the non-nucleoside inhibitor nevirapine (NEV) has been tested. In fact, NEV was able to inhibit cDNA generation at concentration ranging from 50 nM to 100 nM.

	^{a}MIC$_{100}$ (nM)					
Patient code	**AZT**	**3TC**	**TVF**	**PCOAN1**	**PCOAN2**	**PCOAN3**
HAM/TSP #2	10	>1000	>1000	100	100	100
HAM/TSP #3	10	>1000	>1000	>1000	10	10
HAM/TSP #4	100	>1000	>1000	100	100	10
HAM/TSP #5	10	1000	100	100	100	10

Table 7: Susceptibility to NRTI of HTLV-1 RT from isolates of HAM/TSP patients.

^{a}MIC$_{100}$: Minimum Inhibitory Concentration able to inhibit 100% RT activity.

		aMIC$_{100}$ (nM)						
Patient code	Time	AZT	3TC	TVF	PCOAN1	PCOAN2	PCOAN3	NEV
TSP #6	Week 0	6	$>10^3$	10	2	6	4	100
	Week 48	6	$>10^3$	10	2	6	4	50
TSP #7	Week 0	6	$>10^3$	10^2	4	10	6	100
	Week 48	6	$>10^3$	10^2	4	10	6	100
TSP #8	Week 0	6	$>10^3$	10	4	10	8	100
	Week 48	6	$>10^3$	10	4	8	8	50
TSP #9	Week 0	6	$>10^3$	10	6	10	6	100
	Week 48	6	$>10^3$	10	8	10	6	50
TSP #10	Week 0	8	$>10^3$	10^3	8	10	8	75
	Week 48	8	$>10^3$	10^3	8	10	8	100
TSP #11	Week 0	4	4^*10^2	10^2	8	10	10	100
	Week 48				bND			

Table 8: Susceptibility to NRTI and NNRTI of HTLV-1 RT from isolates of HAM/TSP patients before and after treatments, in a dose-response experiment.

aMIC$_{100}$: Minimum Inhibitory Concentration able to inhibit 100% RT activity; bND = Not Done.

**Figure 14:** Susceptibility to NRTIs of HTLV-1 RT from HAM/TSP #4 patients.

4.5 Sensitivity of HTLV-1 isolates from ATLL patients to RT inhibitors.

The third group of patients was a cohort of nine ATLL patients, untreated or treated with AZT plus interferon. For these patients, firstly the HTLV-1 p19 in the supernatants of the cultured PBMCs as a surrogate measure of the amount of RT, was calculated.

Figure 16 shows that the RT activity in the untreated patients (ATLL-3, ATLL-4, ATLL-5, ATLL-6) reached a plateau in the presence of p19 amount between 20 and 25 picograms. Although p19 was detectable in all the four patients tested, its amount was lower than that in the supernatants from chronically infected MT-2 cell line. Figure 17 shows the RT activity of the ATLL (ATLL-1,-2,-7,-8,-9) patients that were enrolled in therapy, before (open square) and after (open triangle) treatment. Only one of out five patients, after treatment, showed an amount of p19 between 15 and 25 pg. All the other patients, after treatment with AZT plus IFN, didn't show any detectable p19 in the supernatants. Then, the samples presenting detectable p19 between were analyzed to test their sensitivity to AZT, 3TC, TVF and nevirapine in the HTLV-1 RT inhibitory activity assay.

The Table 9 shows the minimum inhibitory concentrations of the four compounds towards RT activity. HTLV 1 RT from ATLL patients before and after AZT plus IFN treatment (panel *A*) and not enrolled patients (panel *B*) were variably susceptible to tenofovir and AZT at a concentration range of 1 - 10nM. Only in the case of primary culture from ATLL-4 the RT activity was inhibited by 100 μM AZT. Conversely 3TC and Nevirapine inhibited HTLV-1 RT from ATLL patients at drugs concentrations of 1000 or > 1000 nM.

Figure 16: Dose response of RT activity in HTLV-1 infected cultures. Supernatants of cultures from PBMCs of patients with ATLL not enrolled in AZT plus IFN study (ATLL-3, -4, -5, -6) and from MT-2 cells were assayed for p19 production.

Figure 17: Dose response of RT activity in HTLV-1 infected cultures. Supernatants of cultures from PBMCs of patients with ATLL treated with AZT plus IFN drugs (ATLL-1, -2, -7, -8, -9), before (open square) and after treatment (open triangle), and from MT-2 cells were assayed for p19 production.

			^{a}MIC$_{100}$ (nM)			
Patient code		**Therapy**	**AZT**	**3TC**	**TVF**	**NEV**
A)	*ATLL-1*	^{b}NT	1	>1000	10	>1000
		AZT + IFN		RT undetectable		
	ATLL-2	NT	1	1000	1	>1000
		AZT + IFN		RT undetectable		
	ATLL-7	NT	1	1000	10	>1000
		AZT + IFN		RT undetectable		
	ATLL-8	NT	10	1000	10	>1000
		AZT + IFN	10	1000	1	100
	ATLL-9	NT		RT undetectable.		
		AZT + IFN				
B)	*ATLL-3*	NT	1	>1000	10	>1000
	ATLL-4	NT	100	1000	10	1000
	ATLL-5	NT	10	1000	10	1000
	ATLL-6	NT	1	1000	1	>1000

Table 9: Susceptibility to NRTI and NNRTI of HTLV-1 RT from isolates of ATLL patients, untreated and treated with AZT plus interferon. (panel *A*) or not enrolled in the study (panel *B*).

^{a}MIC$_{100}$: Minimum Inhibitory Concentration able to inhibit 100% RT activity; ^{b}NT: not treated

4.6 Evaluation of *pol* presence in ATLL patients

In order to verify whether the absence of RT activity in the supernatants of primary cultures from treated patients corresponded to a possible, at least partial, remission *in vivo* of the ATLL patients, the presence of HTLV-1 DNA *pol* was evaluated both in qualitative PCR and in Real-Time quantitative PCR, using gene-specific primers and the SybrGreen chemistry.

The presence of *pol* gene in ATLL cell lines was studied by qualitative DNA-PCR (Figure 18), and the *GAPDH* gene has been used as a control. All samples showed the band of *pol* gene (118 bp) like the chronically infected MT2 cell line (panel B), except 3 samples that were from patients which underwent therapy with AZT plus IFN that were ATLL-1, ATLL-2 (panel A) and ATLL-9 (panel B).

Given that three patients after treatment didn't show the presence of the *pol* gene, it was important to quantitatively evaluate the presence of *pol* gene in all the untreated and treated patients enrolled in the study and in the patients ATLL 3, 4, 5 and 6, not enrolled in the study. Results of *pol* DNA were expressed as fold change ($2^{-\Delta\Delta Ct}$) by comparison with values detected in untreated patients. In detail, the Ct values of ATLL patients, available before and after therapy, have been normalized in respect to the untreated sample, as shown in Fig 19 A. On the other hand, the average Ct values of untreated patients was used as baseline to determine the fold change in *pol* gene in patients not enrolled in the study (Fig 19B). Figure 19A shows the results referring to patients under therapy in which ATLL-1, -2 and -9 were negative for *pol*. Conversely *pol* was only partially inhibited in ATLL-7 and not inhibited in ATLL 8 where its value increased of 1.4 folds. In the group of ATLL patients not enrolled in the study, *pol* was variably present and only the ATLL-6 (Figure 19B) reached a value of a 5.1 fold increase.

Figure 18: *pol* gene (118 bp) presence in ATLL patients enrolled and not in AZT plus IFN study, studied by qualitative DNA-PCR.

Figure 19: Evaluation of *pol* quantitative presence in ATLL patients, *in vivo* enrolled in AZT plus IFN therapy (panel A) or not enrolled (panel B)

4.7 Toxicity of the compounds on uninfected cells.

In order to assess levels of toxicity of PCOANs toward uninfected cells, their effects on cell metabolic activity were tested in lymphoid MOLT-3 cells. The cytotoxic effect of the PCOANs on uninfected cells was measured by assaying inhibition of oxygen burst using the MTS assay in the lymphoid cell line MOLT-3. The results, in Table 10, are the means of three experiments and show that the inhibitory effect of PCOANs on cell metabolic activity in MOLT-3 cells was greater than that of TFV but, in any case, extremely low. Also in this case, AZT showed the highest cytotoxic effect in comparison with phosphonate compounds.

Compounds	maCC$_{20}$ (mM [mean ± SD])^a	maCC$_{50}$ (mM [mean ± SD])^a
PCOAN1	480 ± 110	> 10^3
PCOAN2	470 ± 112	> 10^3
PCOAN3	220 ± 13	875 ± 125
TFV	> 10^3	> 10^3
AZT	10 ± 8.1	76.2 ± 15.3

Table 10: Cytotoxicity of the compounds on uninfected cells. ^{a} Cytotoxic activity evaluated as the compound concentration able to cause reduction in formazan product formation (MTS assay) by 20-50% in exponentially growing MOLT-3 cell cultures treated with different concentrations of the compounds for 24h. the data represent results derived from three different experiments.

5. DISCUSSION

In the past years, lack of clear evidence that horizontal transmission of HTLV-1 contributed to maintaining or, indeed, increasing the viral burden in infected patients discouraged the use of antiviral agents for the control of HTLV-1-associated diseases. In fact, the principle that HTLV-1 survived and spread within the host exclusively through proliferation of infected cells negated a rationale for such a therapeutic approach. However, recent advances in HTLV-1 biology, particularly those demonstrating mechanisms involved in direct cell-to-cell transmission of the virus, together with partial results obtained in clinical studies involving antiviral agents for the treatment of HTLV-1-associated diseases, give new impulse to studies aimed at identifying compounds able to efficiently inhibit the HTLV-1 replication cycle. In fact, the overall number of potential antiviral compounds that have been tested on HTLV-1-infection *in vitro* remains limited. Previous data have shown that AZT and tenofovir were able to inhibit in vitro HTLV-1 transmission to peripheral blood mononuclear cells from adult (Macchi B. *et al.*, 1997, Hill S.A. *et al.*, 2003; Balestrieri E. *et al.*, 2005). Conversely, at least two studies have shown that a nucleoside analogue, such as lamivudine, known for its ability to control HIV infection, was not as effective toward HTLV-1 infection in vitro, probably due to some natural resistance (Garcia-Lerma J.G. *et al.*, 2001; Toro C. *et al.*, 2003). Similarly, none of the inhibitors designed to act against the HIV-1 proteases was able to efficiently inhibit Gag processing in HTLV-1-infected cells (Pettit S.C. *et al.*, 1998).

On the other side, in vivo studies have shown that just a few compounds used in HIV therapy were found to be efficient in controlling HTLV-1 infection. Actually IFN and AZT were able to control ATLL disease (Hermine O. *et al.*, 1995), while AZT and lamivudine provided transient effects on viral loads in TSP/HAM patients (Taylor GP *et al.*, 2006). However nowdays clinical trials have directly translated the experience with

drug in HIV infection to HTLV-1 infection, before detailed in vitro investigation to assess the effect of drug on RT from HTLV-1 infected patients. Thus, this study wanted to investigate the effect of antiretroviral drugs in vitro directly on HTLV-1 reverse transcriptase activity from virus isolates from infected patients. In order to investigate this aspect, a sensitive RT inhibitor assay, recently set up in the laboratory where this study has been carried out, has been modified and optimized .

The sensitivity of HTLV-1 primary isolates to AZT, lamivudine, tenofovir and three novel PCOANs has been, then, determined for the first time using this novel RT inhibition assay. In fact, using PBMCs from patients with HAM/TSP or ATLL who had been treated or not with the RT inhibitors AZT plus lamivudine or interferon, the sensitivity of HTLV-1 RT to AZT and to tenofovir has been investigated. Interestingly, it was shown how primary isolates from HTLV-1 infected patients were more sensitive to newly synthesized compounds, PCOANs in respect to the well known tenofovir. On the other side, the primary resistance of HTLV-1 to 3TC and to nevirapine in these clinical isolates has been shown. Furthermore, results indicate that the prolonged *in vivo* treatment with AZT and lamivudine did not result in reduced sensitivity of HTLV-1 RT to these nucleoside analogues. Therefore, it seems plausible to conclude that the lack of viral, and consequent lack of immunological and clinical response seen in this study (Taylor G.P. *et al.*, 2006) was not due to the development of phenotypic resistance. On the other side, cultured cells from mononuclear cells showed that 4 ATLL patients treated with AZT plus interferon were completely negative for RT activity, while 1 was partially negative. Interestingly, 3 out of 5 ATLL patients were also negative for *pol* gene. Moreover, the sensitivity of RT from HTLV-1 patients with that of RT from long term IL-2 dependent or chronically IL-2 independent cell lines was compared. The results indicated that RT from cell lines exhibited variable sensitivity to RT-inhibitors, similar to that detected in cultured cells of

TSP or ATLL patients, except in case of that to tenofovir. The sensitivity to tenofovir of RTs from primary isolates was at least one order of magnitude, and in some cases a thousand times, less than that of RT obtained from MT-2 cells.Two could be the possible reasons underlying these unexpected response to RT inhibitors of isolates from patients. On one side, this can be a stochastic event related to the actual sensitivity to RT inhibitors over a relatively high number of patients and, thus, unrestricted to the primary isolates from HTLV-1 infected patients, but rather present also in chronically infected cell lines, whether assayed in a wider number. Interestingly, recent results from the laboratory where this study has been carried out, demonstrated that RTs from different HTLV-1 transformed cell lines were endowed with different sensitivity to RT inhibitors. PCOAN2 inhibited RT activity in the supernatant from C5MJ and MT-2 at concentration 10-100 lower than that inhibiting RT in the supernatant from C91PL. Tenofovir inhibited RT in the supernatant of MT-2 cells at concentrations 10-100 times less in the supernatant from C91PL, and C5MJ. Conversely RT from the supernatant of HUT 102 was found to be resistant to most of the RT inhibitors used (Balestrieri E. *et al.*, 2008). On the other side, the persistent phenotypic sensitivity of RT from the HTLV-1 isolates to tenofovir suggests that the lack of virological effect in the dual therapy study presumably was not due to the emergence of mutations in RT during therapy. In fact, it seems that lack of sensitivity to tenofovir was present prior to, and not only after treatment, and consequently it should not be altered by any in vivo NRTI exposure. Thus, low sensitivity of RTs from isolates of patients to tenofivir inhibitory effect detected in both treated and untreated patients in vitro might be ascribed to a natural resistance. Phylogenetic studies have recently underlined how amminoacidic variation, even if they are less than 2.5%, in the RT from HTLV-1 isolates belongigng to the cosmopolitan lineage can be selected. Some of these variation from the consensus sequences might be shared among several isolates, but most were unique to a

single HTLV-1 isolate (Mitchell MS *et al.*,2007). These variations could explain the natural resistance to tenofovir both of untreated versus treated samples. This events might recalls what has been recently described for 3TC, whose lacking of effect was ascribed to a natural resistance of HAM/TSP patients to 3TC due to a polymorphism at codon 118 of the reverse transcriptase (Toro C *et al.*, 2003). The genetic stability of HTLV-1 is much higher than tha of HIV, but naturally occurring varities of HTLV-1 RT (Mitchell MS *et al.*, 2007) may also affect in vivo potency of a drug. Anyhow it has to be pointed out how the response of HTLV-1 infected patients to therapy with RT inhibitors is variable. It seems that ATLL patients were more prone to respond to treatment with AZT plus interferon, showing how AZT could be a suitable chemotherapeutic agents in HTLV-1-associated chronic leukaemia. Actually AZT in combination with interferon-α was found to induce remission in vivo in 70% of ATL patiens (Bazarbachi A and Hermine O, 1996) and inhibition of *pol* and RT activity *in vitro* assay. On the other side we have shown that whole virus primary isolates obtained from patients with HAM/TSP and ATLL were highly sensitive to PCOANs which inhibited in vitro RT activity at a RT inhibitory concentration lower than that of AZT suggesting that these compounds should be considered in future studies. Failure to respond to antiretroviral treatment in vivo by HAM/TSP patients, supports the hypothesis that the preferential HTLV-1 transmission route in vivo can be only partially RT-dependent while HTLV-1 viral load maintenance and spread within the patient might be ascribed to the a mitotic route. This evidence suggests that given that HTLV-1 is highly cell-associated virus, RT inhibitors might be more useful in clinical trials if used in combination with other compounds such as modulators of cell signalling (Tan C. and Waldmann T.A., 2002). Alternatively, data of this thesis seem to indicate that AZT rather than tenofovir (unless sensitivity is known) would be the preferred agent following high-risk exposure to prevent HTLV-1 infection.

However, results reported in this thesis should be considered as preleminary and further data must be accumulated in order draw any conclusion on this aspect. Nevertheless, data collected during the course of this thesis suggest the importance of performing *in vitro* screening for possible natural resistance before treatment with RT inhibitors in HTLV-1 infected patients, by means of the described assay that utilizes virus isolates. In fact, it seems that the reported results indicate the possibility to predict, by means of an *ex vivo* cell-free assay, the sensitivity of HTLV-1 to different RT inhibitors using virus isolates from patients.

6. BIBLIOGRAPHY

Ananworanich J., Moor Z., Siangphoe U., Chan J., Cardiello P., Duncombe C., Phanuphak P., Ruxrungtham K., Lange J. and Cooper D.A. Indice and risk factors for rash in Thai patients randomized to regimens whit nevirapine, efavirenz or both drugs. *AIDS* 19: 185-192 2005

Ando, Y; Ekuni, Y; Matsumoto, Y; Nakano, S; Saito, K; Kakimoto, K; Tanigawa, T; Kawa, M; Toyama, T. Long-term serological outcome of infants who received frozen-thawed milk from human T-lymphotropic virus type-I positive mothers. *J Obstet Gynaecol Res.* 2004;**30**:436–438.

Aouba A, **Lambotte O**, **Vasiliu V**, **Divine M**, **Valensi F**, **Varet B**, **Bazarbachi A**, **Hermine O**. Hemophagocytic syndrome as a presenting sign of transformation of smoldering to acute adult T-cell leukemia/lymphoma: efficacy of anti-retroviral and interferon therapy. *Am J Hematol.* 2004 Jun;76(2):187-9.

Ariumi, Y; Kaida, A; Lin, JY; Hirota, M; Masui, O; Yamaoka, S; Taya, Y; Shimotohno, K. HTLV-1 tax oncoprotein represses the p53-mediated trans-activation function through coactivator CBP sequestration. *Oncogene.* 2000;**19**:1491–1499.

Asquith B, **Zhang Y**, **Mosley AJ**, **de Lara CM**, **Wallace DL**, **Worth A**, **Kaftantzi L**, **Meekings K**, **Griffin GE**, **Tanaka Y**, **Tough DF**, **Beverley PC**, **Taylor GP**, **Macallan DC**, **Bangham CR**. In vivo T lymphocyte dynamics in humans and the impact of human T-lymphotropic virus 1 infection. *Proc Natl Acad Sci U S A*. 2007 May 8;104(19):8035-40. Epub 2007 May 1.

Azran, I; Schavinsky-Khrapunsky, Y; Aboud, M. Role of Tax protein in human T-cell leukemia virus type-I leukemogenicity. *Retrovirology.* 2004;**1**:20.

Balestrieri E., Forte G., Matteucci C., Mastino A. and Macchi B. Effect of Lamivudine on transmission of human T-cell lymphotropic virus type I to adult peripheral blood

mononuclear cells *in vitro. Antimicrobical Agents and Chemotherapy* 46: 3080-3083. 2002

Balestrieri E., Sciortino M.T., Mastino A. and Macchi B. Protective effect of acyclic nucleoside phosphonate tenofovir toward human T-cell leucemia/lymphotropic virus type I infection of human peripheral blood mononuclear cells *in vitro. Antiviral Res.* 68:154-62. 2005.

Balestrieri E., Matteucci C., Ascolani A., Piperno A., Romeo R., Romeo G., Chiacchio U., Mastino A. and Macchi B. Effect of phosphonated carbocyclic 2'-oxa-3'-aza-nucleoside on HTLV-1 infection *in vitro. Antimicrobical Agents and Chemotherapy* 52(1): 54-64. 2008

Bazarbachi A, Hermine O. Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. *J Acquir Immune Defic Syndr Hum Retrovirol.* 1996;13 Suppl 1:S186-90.

Bazarbachi A, Nasr R, El-Sabban ME, Mahé A, Mahieux R, Gessain A, Darwiche N, Dbaibo G, Kersual J, Zermati Y, Dianoux L, Chelbi-Alix MK, de Thé H, Hermine O. Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma. *Leukemia.* 2000 Apr;14(4):716-21.

Basbous, J; Arpin, C; Gaudray, G; Piechaczyk, M; Devaux, C; Mesnard, JM. The HBZ factor of human T-cell leukemia virus type I dimerizes with transcription factors JunB and c-Jun and modulates their transcriptional activity. *J Biol Chem.* 2003;**278**:43620–43627.

Bhigjee AI, **Bill PL**, **Wiley CA**, **Windsor IM**, **Matthias DA**, **Amenomori T**, **Wachsman W**, **Moorhouse D**. Peripheral nerve lesions in HTLV-I associated myelopathy (HAM/TSP). *Muscle Nerve.* 1993 Jan;16(1):21-6.

Birkus G., Hitchcock M.J. and Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase

inhibitors. *Antimicrob Agents Chemother*: 46: 716-23. 2002

Bittencourt AL, Dourado I, Filho PB, Santos M, Valadão E, Alcantara LC, Galvão-Castro B. Human T-cell lymphotropic virus type 1 infection among pregnant women in northeastern Brazil. *J Acquir Immune Defic Syndr.* 2001 Apr 15;26(5):490-4.

Blattner, WA; Gallo, RC. Epidemiology of HTLV-I and HTLV-II infection. In: Takahashi K. , editor. *Adult T-cell leukemia.* New York, Oxford University Press; 1994. pp. p.45–90.

Calattini S, Chevalier S, Duprez R, Afonso P, Froment A, Gessain A, Mahieux R . Human T-cell lymphotropic virus type 3: complete nucleotide sequence and characterization of the human tax3 protein. *J Virol* **80** (19): 9876–88. 2006.

Cartier L, **Vergara C**, **Ramírez E**, **Casivar T**, **Vásquez A**. Seroprevalence of HTLV-I in relatives of patients with spastic paraparesis (HAM/TSP and PEP). *Rev Med Chil.* 1995 Jan;123(1):7-11.

Chang C.N., Doong S.L., Zhou J.H., Beach W., Jeong L.S., Chu C.K., Tsai C. and Cheng Y. Deoxycitidine deaminase-resistant stereoisomer is the active form of 2', 3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication. *Journal of Biological Chemistry* 267: 13938-13942. 1992

Chang C.N., Skalski V., Zhou J.H. and Cheng Y.C. **Biochemical pharmacology of (+)-and (-)-2',3'-dideoxy-3'-thiacytidine as anti-hepatitis B virus agents. *J. Biol .Chem.* 5; 267: 22414-22420. 1992**

Chiacchio U, Corsaro A, Iannazzo D, Piperno A, Pistara V, Rescifina A, et al. Enantioselective Syntheses and Cytotoxicity of N,O-Nucleosides. *J Med Chem*;46(17):3696-702. 2003

Chiacchio U, Balestrieri E, Macchi B, Iannazzo D, Piperno A, Rescifina A, et al. Synthesis of Phosphonated Carbocyclic 2'-Oxa-3'-aza-nucleosides: Novel Inhibitors of

Reverse Transcriptase. *J Med Chem*;48(5):1389-94. 2005

Chiacchio U, Rescifina A, Iannazzo D, Piperno A, Romeo R, Borrello L, et al. Phosphonated Carbocyclic 2'-Oxa-3'- aza-nucleosides as new antiretroviral agents. *J Med Chem*;50:3747-50. 2007.

Chiavetta JA, **Escobar M**, **Newman A**, **He Y**, **Driezen P**, **Deeks S**, **Hone DE**, **O'Brien SF**, **Sher G**. Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000. *CMAJ*. 2003 Oct 14;169(8):767-73.

Coffin J.M. Retroviridae: the viruses and their replication. In *Fields Virology*, 3rd edition. Vol. 2, Eds. Fields B.N., Knipe D.M., Howley P.M. 1996

Copeland WC, Chen MS, Wang TS. Human DNA polymerases alpha and beta are able to incorporate anti-HIV deoxynucleotides into DNA. *J Biol Chem.* 1992 Oct 25;267(30):21459-64.

Couroucé AM, **Pillonel J**, **Lemaire JM**, **Maniez M**, **Brunet JB**. Seroepidemiology of HTLV-I/II in universal screening of blood donations in France. *AIDS* 1993 Jun;7(6):841-7.

Croda MG, de Oliveira AC, Vergara MP, Bonasser F, Smid J, Duarte AJ, Casseb J. Corticosteroid therapy in TSP/HAM patients: the results from a 10 years open cohort. *J Neurol Sci.* 2008 Jun 15;269(1-2):133-7. Epub 2008 Feb 6.

Cundy K.C., Sueoka C., Lynch G.R., Griffin L., Lee W.A. and Shaw J.P. Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. *Antimicrob Agents Chemother.* 42: 687-90. 1998

Cupps TR, Fauci AS. Corticosteroid-mediated immunoregulation in man. *Immunol Rev.* 1982;65:133-55.

De Clercq E. Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections. *Expert Rev Anti Infect Ther.* 2003 Jun;1(1):21-43.

De Clercq E. Clinical potential of the acyclic nucleoside phosphonates Cidofovir, Adefovir, and Tenofovir in treatment of DNA virus and retrovirus infections. *Clinical Micobiolgy Review* Oct 2003; vol 16 No 4: 569-596.

De Clercq E. and Holy A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. *Nature*, reviews. vol.4: 928-939. 2005

De Santis M., Carducci B., De Santis L., Cavaliere A.F. and Straface G. Periconceptional exposure to efavirenz and neuronal tube defects. *Arch. Intern. Med.* 162: 355. 2002.

de Thé G, **Kazanji M**. An HTLV-I/II vaccine: from animal models to clinical trials? *J Acquir Immune Defic Syndr Hum Retrovirol.* 1996;13 Suppl 1:S191-8.

Del Mistro A., De Rossi A., Aldavini A., Salmi R and Chieco Bianchi L. Immortalization of lynphocytes by HTLV-1: phenotipic characteristic of target cells and kinetics of virus integration and expression. *Leukemia Research* 10: 1109-1120. 1986

Derse D, Hill SA, Lloyd PA, Chung Hk, Morse BA. Examining human T-lymphotropic virus type 1 infection and replication by cell-free infection with recombinant virus vectors. *J Virol.* 2001 Sep;75(18):8461-8.

Di Venuti G, Nawgiri R, Foss F. Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated acute T-cell leukemia/lymphoma. *Clin Lymphoma* 2003;4:176–8.

Eberle J, Seibl R. A new method for measuring reverse transcriptase activity by ELISA. *J Virol Methods.* 1992 Dec 1;40(3):347-56.

Endo, K; Hirata, A; Iwai, K; Sakurai, M; Fukushi, M; Oie, M; Higuchi, M; Hall, WW; Gejyo, F; Fujii, M. Human T-cell leukemia virus type 2 (HTLV-2) Tax protein

transforms a rat fibroblast cell line but less efficiently than HTLV-1 Tax. *J Virol.* 2002;**76**:2648–2653.

Ferreira OC Jr, **Planelles V**, **Rosenblatt JD**. Human T-cell leukemia viruses: epidemiology, biology, and pathogenesis. *Blood Rev.* 1997 Jun;11(2):91-104.

Franchini G, **Fukumoto R**, **Fullen JR**. T-cell control by human T-cell leukemia/lymphoma virus type 1. *Int J Hematol.* 2003 Nov;78(4):280-96.

Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, Lehrman SN, Bolognesi DP, Broder S, Mitsuya H, et al. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. *Proc Natl Acad Sci U S A.* 1986 Nov;83(21):8333-7.

Garcia-Lerma JG, Nidtha S, Heneine W. Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine. *J Infect Dis* 2001;184:507–10.

Geiger TR, **Sharma N**, **Kim YM**, **Nyborg JK**. The human T-cell leukemia virus type 1 tax protein confers CBP/p300 recruitment and transcriptional activation properties to phosphorylated CREB. *Mol Cell Biol.* 2008 Feb;28(4):1383-92. Epub 2007 Dec 10.

Gessain A, Barin F, Vernant JC et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985; 2: 7415-7419.

Gessain A, **Gout O**. Chronic myelopathy associated with human T-lymphotropic virus type I (HTLV-I). *Ann Intern Med.* 1992 Dec 1;117(11):933-46.

Goon P, Igakura T, Hanon E, Mosley AJ, Barfield A, Barnard A, et al. HTLV-1 specific CD4+ T cells: Immunodominance hierarchy and preferential infection with HTLV-1. *J Immunol* 2004;172(3):1735-43.

Gout O, Gessain A, Iba-Zizen M, Kouzan S, Bolgert F, de Thé G, Lyon-Caen O. The

effect of zidovudine on chronic myelopathy associated with HTLV-1. *J Neurol.* 1991 Apr;238(2):108-9.

Grob P.M., Wu J.C., Cohen K.A. Ingraham R.H., Shih C.K., Hargrave K.D., McTague T.L. and Marluzzi V.J. Non nucleoside inhibitors of HIV-1 reverse-trascriptase: nevirapine as a prototype drug. *AIDS res. Hum. Retroviruses* 8: 145-152. 1992

Harrington WJ Jr, Sheremata WA, Snodgrass SR, Emerson S, Phillips S, Berger JR. Tropical spastic paraparesis/HTLV-1-associated myelopathy (HAM/TSP): treatment with an anabolic steroid danazol. *AIDS Res Hum Retroviruses.* 1991 Dec;7(12):1031-4.

Hermine O, Bouscary D, Gessain A, Turlure P, Leblond V, Franck N, Buzyn-Veil A, Rio B, Macintyre E, Dreyfus F, et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. *N Engl J Med.* 1995 Jun 29;332(26):1749-51.

Hill SA, **Lloyd PA**, **McDonald S**, **Wykoff J**, **Derse D**. Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors. *J Infect Dis.* 2003 Aug 1;188(3):424-7. Epub 2003 Jul 10.

Hino, S. Primary prevention of ATL. In: Sugamura K, Uchiyama T, Matsuoka M and Kannagi M. , editor. *Two decades of adult T-cell leukemia and HTLV-I research.* Tokyo, Japan Sicentific Societies Press; 2003. pp. 241–251.

Hirata, A; Higuchi, M; Niinuma, A; Ohashi, M; Fukushi, M; Oie, M; Akiyama, T; Tanaka, Y; Gejyo, F; Fujii, M. PDZ domain-binding motif of human T-cell leukemia virus type 1 Tax oncoprotein augments the transforming activity in a rat fibroblast cell line. *Virology.* 2004;**318**:327–336.

Igakura T., Stinchcombe J.C., Goon P.K.C., Taylor G.P., Weber J.N., Griffiths G.M., Tanaka Y., Osame M. and Bangham C.R.M. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. *Science* 299: 1713-1716. 2003

Ishida T, Iida S, Akatsuka Y, *et al.* The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma. *Clin Cancer Res* 2004;10:7529–39.

Ishitsuka K, Hanada S, Suzuki S, *et al.* Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids. *Br J Haematol* 1998;103:721–8.

Ishitsuka K, Ikeda R, Utsunomiya A, *et al.* Arsenic trioxide induces apoptosis in HTLV-I infected T-cell lines and fresh adult T-cell leukemia cells through CD95 or tumor necrosis factor alpha receptor independent caspase activation. *Leuk Lymphoma* 2002;43:1107–14.

Ishitsuka K, **Tamura K**. Treatment of adult T-cell leukemia/lymphoma: past, present, and future. *Eur J Haematol.* 2008 Mar;80(3):185-96. Epub 2007 Dec 10.

Iwasaki Y. Pathology of chronic myelopathy associated with HTLV-I infection (HAM/TSP). *J Neurol Sci.* 1990 Apr;96(1):103-23.

Izumo S, Goto I, Itoyama Y, Okajima T, Watanabe S, Kuroda Y, Araki S, Mori M, Nagataki S, Matsukura S, Akamine T, Nakagawa M, Yamamoto I, Osame M. Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial. *Neurology.* 1996 Apr;46(4):1016-21.

Jacobson S. Immunopathogenesis of human T cell lymphotropic virus type I-associated neurologic disease. *J Infect Dis.* 2002 Dec 1;186 Suppl 2:S187-92.

Jeang KT, **Widen SG**, **Semmes OJ 4th**, **Wilson SH**. HTLV-I trans-activator protein, tax, is a trans-repressor of the human beta-polymerase gene. *Science.* 1990 Mar 2;247(4946):1082-4.

Jeang, KT; Giam, CZ; Majone, F; Aboud, M. Life, death, and tax: role of HTLV-I oncoprotein in genetic instability and cellular transformation. *J Biol Chem.*

2004;**279**:31991–31994. Life, death, and tax: role of HTLV-I oncoprotein in genetic instability and cellular transformation. *J Biol Chem.* 2004;**279**:31991–31994.

Johnson J.M., Harrod R. and Franchini G. Molecular biology and pathogenesis of the human T-cell leukaemia/lymphotropic virus type I (HTLV-1). *Int. J. Exp. Pathol.* 82: 135-147. 2001

Kamada, N; Sakurai, M; Miyamoto, K; Sanada, I; Sadamori, N; Fukuhara, S; Abe, S; Shiraishi, Y; Abe, T; Kaneko, Y, et al. Chromosome abnormalities in adult T-cell leukemia/lymphoma: a karyotype review committee report. *Cancer Res.* 1992;**52**:1481–1493.

Kaplan JE, **Osame M**, **Kubota H**, **Igata A**, **Nishitani H**, **Maeda Y**, **Khabbaz RF**, **Janssen RS**. The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. *J Acquir Immune Defic Syndr.* 1990;3(11):1096-101.

Kawakami, H; Tomita, M; Matsuda, T; Ohta, T; Tanaka, Y; Fujii, M; Hatano, M; Tokuhisa, T; Mori, N. Transcriptional activation of survivin through the NF-kappaB pathway by human T-cell leukemia virus type I tax. *Int J Cancer.* 2005.

Kira J, **Itoyama Y**, **Koyanagi Y**, **Tateishi J**, **Kishikawa M**, **Akizuki S**, **Kobayashi I**, **Toki N**, **Sueishi K**, **Sato H, et al**. Presence of HTLV-I proviral DNA in central nervous system of patients with HTLV-I-associated myelopathy. *Ann Neurol.* 1992 Jan;31(1):39-45.

Koyanagi Y, Itoyama Y, Nakamura, N; Takamatsu, K; Kira, J; Iwamasa, T; Goto, I; Yamamoto, N. In vivo infection of human T-cell leukemia virus type I in non-T cells. *Virology.* 1993;**196**:25–33.

Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, Waldmann TA, Pastan I. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38

(LMB-2) in patients with hematologic malignancies. *J Clin Oncol* 2000;18:1622–36.

Lee H., Hanes J. and Johnson K.A. Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. *Biochemistry* 42: 14711-14719. 2003

Lee MH, Sano K, Morales FE, Imagawa DT. Sensitive reverse transcriptase assay to detect and quantitate human immunodeficiency virus. *J Clin Microbiol.* 1987 Sep;25(9):1717-21.

Lee, DK; Kim, BC; Brady, JN; Jeang, KT; Kim, SJ. Human T-cell Lymphotropic Virus Type 1 Tax Inhibits Transforming Growth Factor-beta Signaling by Blocking the Association of Smad Proteins with Smad-binding Element. *J Biol Chem.* 2002;**277**:33766–33775.

Lehky TJ, **Fox CH**, **Koenig S**, **Levin MC**, **Flerlage N**, **Izumo S**, **Sato E**, **Raine CS**, **Osame M**, **Jacobson S**. Detection of human T-lymphotropic virus type I (HTLV-I) tax RNA in the central nervous system of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by in situ hybridization. *Ann Neurol.* 1995 Feb;37(2):167-75.

Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, Coffin JM, Bosch RJ, Margolis DM. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. *Lancet.* 2005 Aug 13-19;366(9485):549-55.

Levin MC, **Jacobson S**. Cellular and humoral immune responses associated with HTLV-I associated myelopathy/tropical spastic paraparesis. *Ann N Y Acad Sci.* 1997 Dec 19;835:142-52.

Lezin A, Gillet N, Olindo S, Signate A, Grandvaux N, Verlaeten O, et al. Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1 associated myelopathy/tropical spastic paraparesis patients. *Blood* 2007 Nov

15;110(10):3722-8.

Lezin A, Gillet N, Olindo S, Signaté A, Grandvaux N, Verlaeten O, Belrose G, de Carvalho Bittencourt M, Hiscott J, Asquith B, Burny A, Smadja D, Césaire R, Willems L. Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1 associated myelopathy/tropical spastic paraparesis patients. *Blood.* 2007 Nov 15;110(10):3722-8. Epub 2007 Aug 23.

Macchi B, Faraoni I, Zhang J, Grelli S, Favalli C, Mastino A, Bonmassar E. AZT inhibits the transmission of human T cell leukaemia/lymphoma virus type I to adult peripheral blood mononuclear cells in vitro. *J Gen Virol* 1997;78(Pt 5):1007–16.

Macchi B, Balestrieri E, Mastino A. Effects of nucleoside-based antiretroviral chemotherapy on human T cell leukaemia/lymphotropic virus type 1 (HTLV-1) infection in vitro. *J Antimicrob Chemother.* 2003 Jun;51(6):1327-30. Epub 2003 Apr 25.

Machuca A, Soriano V. In vivo fluctuation of HTLV-I and HTLV-II proviral load in patients receiving antiretroviral drugs. *J Acquir Immune Defic Syndr.* 2000 Jun 1;24(2):189-93.

Machuca A, Rodés B, Soriano V. The effect of antiretroviral therapy on HTLV infection. *Virus Res.* 2001 Oct 30;78(1-2):93-100.

Mahieux R, Gessain A . New human retroviruses: HTLV-3 and HTLV-4. *Med Trop (Mars)* **65** (6): 525–8. 2005

Manel, N; Kim, FJ; Kinet, S; Taylor, N; Sitbon, M; Battini, JL. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. *Cell.* 2003;**115**:449–459.

Manns A, **Miley WJ**, **Wilks RJ**, **Morgan OS**, **Hanchard B**, **Wharfe G**, **Cranston B**, **Maloney E**, **Welles SL**, **Blattner WA**, **Waters D**. Quantitative proviral DNA and antibody levels in the natural history of HTLV-I infection. *J Infect Dis.* 1999 Nov;180(5):1487-93.

Matsumoto, J; Ohshima, T; Isono, O; Shimotohno, K. HTLV-1 HBZ suppresses AP-1 activity by impairing both the DNA-binding ability and the stability of c-Jun protein. *Oncogene.* 2005;**24**:1001–1010.

Matsuoka M, **Jeang KT**. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. *Nat Rev Cancer.* 2007 Apr;7(4):270-80.

Matsushita S, Mitsuya H, Reitz MS, Broder S. Pharmacological inhibition of in vitro infectivity of human T lymphotropic virus type I. *J Clin Invest* 1987;80:394–400.

Matsuzaki T, **Nakagawa M**, **Nagai M**, **Usuku K**, **Higuchi I**, **Arimura K**, **Kubota H**, **Izumo S**, **Akiba S**, **Osame M**. HTLV-I proviral load correlates with progression of motor disability in HAM/TSP: analysis of 239 HAM/TSP patients including 64 patients followed up for 10 years. *J Neurovirol.* 2001 Jun;7(3):228-34.

Matutes E, **Spittle MF**, **Smith NP**, **Eady RA**, **Catovsky D**. The first report of familial adult T-cell leukaemia lymphoma in the United Kingdom. *Br J Haematol.* 1995 Mar;89(3):615-9.

Matutes E. Adult T-cell leukaemia/lymphoma**.** *J Clin Pathol.* 2007 Dec;60(12):1373-7.

Medici MA, Sciortino MT, Perri C, Amici E, Avitabile E, Ciotti M, et al. Protection by herpes simplex virus glycoprotein D against Fas-medianted apoptosis: role of nuclear factor kappa B. J Biol Chem 2003;278:36059-67.

Mistry AR, Pedersen EW, Solomon E, Grimwade D. The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. *Blood Rev* 2003;17:71–97.

Mitchell MS, Bodine ET, Hill S, Princler G, Lloyd P, Mitsuya H, Matsuoka M, Derse D. Phenotypic and genotypic comparisons of human T-cell leukemia virus type 1 reverse transcriptases from infected T-cell lines and patient samples. *J Virol.* 2007 May;81(9):4422-8. Epub 2007 Feb 7.

Moore GR, **Traugott U**, **Scheinberg LC**, **Raine CS**. Tropical spastic paraparesis: a model of virus-induced, cytotoxic T-cell-mediated demyelination? *Ann Neurol.* 1989 Oct;26(4):523-30.

Mori, N; Morishita, M; Tsukazaki, T; Giam, CZ; Kumatori, A; Tanaka, Y; Yamamoto, N. Human T-cell leukemia virus type I oncoprotein Tax represses Smad-dependent transforming growth factor beta signaling through interaction with CREB-binding protein/p300. *Blood.* 2001;**97**:2137–2144.

Mueller N, **Okayama A**, **Stuver S**, **Tachibana N**. Findings from the Miyazaki Cohort Study. *J Acquir Immune Defic Syndr Hum Retrovirol.* 1996;13 Suppl 1:S2-7.

Mueller N. The epidemiology of HTLV-I infection. *Cancer Causes Control.* 1991 Jan;2(1):37-52.

Murphy EL, **Watanabe K**, **Nass CC**, **Ownby H**, **Williams A**, **Nemo G**. Evidence among blood donors for a 30-year-old epidemic of human T lymphotropic virus type II infection in the United States. *J Infect Dis.* 1999 Dec;180(6):1777-83.

Murphy R and Montaner J. Nevirapine: a review of its development, pharmacological profile and potential for clinical use. *Exp Opin Invest Drugs* 1996 5 1183-1199.

Nakagawa M, Nakahara K, Maruyama Y, Kawabata M, Higuchi I, Kubota H, Izumo S, Arimura K, Osame M. Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/ tropical spastic paraparesis. *J Neurovirol.* 1996 Oct;2(5):345-55.

Nakagawa M, **Izumo S**, **Ijichi S**, **Kubota H**, **Arimura K**, **Kawabata M**, **Osame M**. HTLV-I-associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings. *J Neurovirol.* 1995 Mar;1(1):50-61.

Neumüller M, Karlström AR, Källander CF, Gronowitz JS. Improved assays for DNA-polymerizing enzymes by the use of enzymatically synthesized 5-[125I]iodo-2'-deoxyuridine triphosphate, illustrated by direct quantitation of anti-HIV reverse

transcriptase antibody and by serum DNA polymerase analyses. *Biotechnol Appl Biochem.* 1990 Feb;12(1):34-56.

Ng PW, **Iha H**, **Iwanaga Y**, **Bittner M**, **Chen Y**, **Jiang Y**, **Gooden G**, **Trent JM**, **Meltzer P**, **Jeang KT**, **Zeichner SL**. Genome-wide expression changes induced by HTLV-1 Tax: evidence for MLK-3 mixed lineage kinase involvement in Tax-mediated NF-kappaB activation. *Oncogene.* 2001 Jul 27;20(33):4484-96.

Nicot, C; Mahieux, R; Takemoto, S; Franchini, G. Bcl-X(L) is up-regulated by HTLV-I and HTLV-II in vitro and in ex vivo ATLL samples. *Blood.* 2000;**96**:275–281.

Nicot, C; Dundr, M; Johnson, JM; Fullen, JR; Alonzo, N; Fukumoto, R; Princler, GL; Derse, D; Misteli, T; Franchini, G. HTLV-1-encoded p30(II) is a post-transcriptional negative regulator of viral replication. *Nat Med.* 2004;**10**:197–201.

Nicot C, **Harrod RL**, **Ciminale V**, **Franchini G**. Human T-cell leukemia/lymphoma virus type 1 nonstructural genes and their functions. *Oncogene.* 2005 Sep 5;24(39):6026-34.

Nishimura S, **Asou N**, **Suzushima H**, **Okubo T**, **Fujimoto T**, **Osato M**, **Yamasaki H**, **Lisha L**, **Takatsuki K**. p53 gene mutation and loss of heterozygosity are associated with increased risk of disease progression in adult T cell leukemia. *Leukemia.* 1995 Apr;9(4):598-604.

Núñez M, Lana R, Mendoza JL, Martín-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. *J Acquir Immune Defic Syndr.* 2001 Aug 15;27(5):426-31.

Oh U, Jacobson S. Treatment of HTLV-I-associated myelopathy/tropical spastic paraparesis: toward rational targeted therapy. *Neurol Clin.* 2008 Aug;26(3):781-97, ix-x.

Ohara Y, **Honma M**, **Iwasaki Y**. Sensitivity of the polymerase chain reaction for detecting human T-cell leukemia virus type I sequences in paraffin-embedded tissue. Effect of unbuffered formalin fixation. *J Virol Methods.* 1992 Apr;37(1):83-8.

Ohno R, Masaoka T, Shirakawa S, *et al.* Treatment of adult T-cell leukemia/lymphoma with MST-16, a new oral antitumor drug and a derivative of bis(2,6-dioxopiperazine). The MST-16 Study Group. *Cancer* 1993;**71**:2217–21.

Okochi, K; Sato, H; Hinuma, Y. A retrospective study on transmission of adult T cell leukemia virus by blood transfusion: seroconversion in recipients. *Vox Sang.* 1984;**46**:245–253.

Osame M, Igata A, Matsumoto M, Tara M. HTLV-I-associated myelopathy. *Gan To Kagaku Ryoho.* 1987 Aug;14(8):2411-6.

Osborne GE, Pagliuca A, Ho A, du Vivier AW. Novel treatment of Sézary-like syndrome due to adult T-cell leukaemia/lymphoma with daclizumab (humanized anti-interleukin-2 receptor alpha antibody). *Br J Dermatol.* 2006 Sep;155(3):617-20.

Palumbo E. Lamivudine for chronic hepatitis B: a brief review. *Braz J Infect Dis.* 2008 Oct;12(5):355-7.

Pettit SC, Sanchez R, Smith T, Wehbie R, Derse D, Swanstrom R. HIV type 1 protease inhibitors fail to inhibit HTLV-I Gag processing in infected cells. *AIDS Res Hum Retroviruses.* 1998 Jul 20;14(11):1007-14.

Pise-Masison, CA; Mahieux, R; Jiang, H; Ashcroft, M; Radonovich, M; Duvall, J; Guillerm, C; Brady, JN. Inactivation of p53 by human T-cell lymphotropic virus type 1 Tax requires activation of the NF-kappaB pathway and is dependent on p53 phosphorylation. *Mol Cell Biol.* 2000;**20**:3377–3386.

Poiesz B.J., Ruscetti F.W., Gadzar A.F., Bunn P.A., Minna J.D. and Gallo R.C. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. *Proc. Natl. Acad. Sci. USA* 77: 7415-7429. 1980

Pombo-de-Oliveira MS, **Tabak DG**. The significance of phenotyping leukemias using

monoclonal antibodies. *Braz J Med Biol Res.* 1990;23(9):763-72.

Portis, T; Harding, JC; Ratner, L. The contribution of NF-kappa B activity to spontaneous proliferation and resistance to apoptosis in human T-cell leukemia virus type 1 Tax-induced tumors. *Blood.* 2001;**98**:1200–1208.

Proietti FA, Carneiro-Proietti ABF, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene 2005; 24: 6058-6068.

Pyra H, Böni J, Schüpbach J. Ultrasensitive retrovirus detection by a reverse transcriptase assay based on product enhancement. *Proc Natl Acad Sci U S A.* 1994 Feb 15;91(4):1544-8.

Robbins B.L., Srinivas R.V., Kim C., Bischofberger N. and Fridland A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2- phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl) PMPA. *Antimicrob. Agents Chemother.* 42: 612-617. 1998

Rosin, O; Koch, C; Schmitt, I; Semmes, OJ; Jeang, KT; Grassmann, R. A human T-cell leukemia virus Tax variant incapable of activating NF-kappaB retains its immortalizing potential for primary T-lymphocytes. *J Biol Chem.* 1998;**273**:6698–6703.

Sadamori N, **Mine M**, **Hakariya S**, **Ichiba M**, **Kawachi T**, **Itoyama T**, **Nakamura H**, **Tomonaga M**, **Hayashi K**. Clinical significance of beta 2-microglobulin in serum of adult T cell leukemia. *Leukemia.* 1995 Apr;9(4):594-7.

Saito M, Nakagawa M, Kaseda S, Matsuzaki T, Jonosono M, Eiraku N, Kubota R, Takenouchi N, Nagai M, Furukawa Y, Usuku K, Izumo S, Osame M. Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-alpha therapy for HTLV-I-associated myelopathy/tropical

spastic paraparesis. *J Infect Dis.* 2004 Jan 1;189(1):29-40. Epub 2003 Dec 31.

Sheremata WA, Benedict D, Squilacote DC, Sazant A, DeFreitas E. High-dose zidovudine induction in HTLV-I-associated myelopathy: safety and possible efficacy. *Neurology.* 1993 Oct;43(10):2125-9.

Shimoyama M, **Tobinai K**, **Yamaguchi K**, **Hirashima K**, **Itoh S**, **Konishi H**, **Mikuni C**, **Togawa A**, **Hotta T**, **Toyoda N, et al**. Treatment of hairy cell leukemia with deoxycoformycin (YK-176). The Deoxycoformycin (YK-176) Study Group. *Jpn J Clin Oncol.* 1992 Dec;22(6):406-10.

Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). *Br J Haematol.* 1991 Nov;79(3):428-37.

Shirabe S, Nakamura T, Tsujino A, Nishiura Y, Furuya T, Goto H, Suenaga A, Nakane S, Yoshimura T, Nagataki S. Successful application of pentoxifylline in the treatment of HTLV-I associated myelopathy. *J Neurol Sci.* 1997 Oct 3;151(1):97-101.

Shirono K, **Hattori T**, **Takatsuki K**. A new classification of clinical stages of adult T-cell leukemia based on prognosis of the disease. *Leukemia.* 1994 Nov;8(11):1834-7.

Shuh M. and Beilke M. The human T-cell leukemia virus type 1 (HTLV-1): new insights into the clinical aspects and molecular pathogenesis of adult T-cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV-associated myelopathy (HAM/TSP). *Microsc. Res. Tech.* 68: 176-96. 2005

Silver J, Maudru T, Fujita K, Repaske R. An RT-PCR assay for the enzyme activity of reverse transcriptase capable of detecting single virions. *Nucleic Acids Res.* 1993 Jul 25;21(15):3593-4.

Stein D.S. and Moore K.H. Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians. *Pharmacotherapy* 21: 11-34. 2001

Stigum H, **Magnus P**, **Samdal HH**, **Nord E**. Human T-cell lymphotropic virus testing of blood donors in Norway: a cost-effect model. *Int J Epidemiol.* 2000 Dec;29(6):1076-84.

Suzuki, T; Uchida-Toita, M; Yoshida, M. Tax protein of HTLV-1 inhibits CBP/p300-mediated transcription by interfering with recruitment of CBP/p300 onto DNA element of E-box or p53 binding site. *Oncogene.* 1999;**18**:4137–4143.

Tamura K, **Unoki T**, **Sagawa K**, **Aratake Y**, **Kitamura T**, **Tachibana N**, **Ohtaki S**, **Yamaguchi K**, **Seita M**. Clinical features of OKT4+/OKT8+ adult T-cell leukemia. *Leuk Res.* 1985;9(11):1353-9.

Tan C, Waldmann TA. Proteasome Inhibitor PS-341, a Potential Therapeutic Agent for Adult T-Cell Leukemia. *Cancer Res* 2002 Feb 1;62(4):1083-6.

Taylor GP, Hall SE, Navarrete S, Michie CA, Davis R, Witkover AD, Rossor M, Nowak MA, Rudge P, Matutes E, Bangham CR, Weber JN. Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy. *J Virol.* 1999 Dec;73(12):10289-95.

Taylor GP, Bodeus M, Courtois F, Pauli G, Del Mistro A, Machuca A, Padua E, Andersson S, Goubau P, Chieco-Bianchi L, Soriano V, Coste J, Ades AE and Weber JN. The seroepidemiology of human T-lymphotropic viruses: types I and II in Europe: a prospective study of pregnant women. (2005) *J. Acq. Immun. Def. Synd.* 38: 104−109.

Taylor GP, Goon P, Furukawa Y, Green H, Barfield A, Mosley A, Nose H, Babiker A, Rudge P, Usuku K, Osame M, Bangham CR, Weber JN. Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial. *Retrovirology.* 2006 Sep 19;3:63

Toro C, **Rodés B**, **Mendoza C**, **Soriano V**. Lamivudine resistance in human T-cell leukemia virus type 1 may be due to a polymorphism at codon 118 (V-->I) of the reverse

transcriptase. *Antimicrob Agents Chemother.* 2003 May;47(5):1774;author reply 1774-5.

Tseliou PM, **Spanakis N**, **Spiliotakara A**, **Politis C**, **Legakis NJ**, **Tsakris A**. HTLV-I and -II in southwestern Greece. *Transfusion.* 2003 Nov;43(11):1641-2.

Tsukahara, T; Kannagi, M; Ohashi, T; Kato, H; Arai, M; Nunez, G; Iwanaga, Y; Yamamoto, N; Ohtani, K; Nakamura, M; Fujii, M. Induction of Bcl-x(L) expression by human T-cell leukemia virus type 1 Tax through NF-kappaB in apoptosis-resistant T-cell transfectants with Tax. *J Virol.* 1999;**73**:7981–7987.

Uchiyama T. Human T cell leukemia virus type I (HTLV-I) and human diseases. *Annu. Rev. Immunol.* 15: 15-37. 1997

Umehara F, **Izumo S**, **Ronquillo AT**, **Matsumuro K**, **Sato E**, **Osame M**. Cytokine expression in the spinal cord lesions in HTLV-I-associated myelopathy. *J Neuropathol Exp Neurol.* 1994 Jan;53(1):72-7.

Umehara F, **Nakamura A**, **Izumo S**, **Kubota R**, **Ijichi S**, **Kashio N**, **Hashimoto K**, **Usuku K**, **Sato E**, **Osame M**. Apoptosis of T lymphocytes in the spinal cord lesions in HTLV-I-associated myelopathy: a possible mechanism to control viral infection in the central nervous system. *J Neuropathol Exp Neurol.* 1994 Nov;53(6):617-24.

Umehara F, **Izumo S**, **Takeya M**, **Takahashi K**, **Sato E**, **Osame M**. Expression of adhesion molecules and monocyte chemoattractant protein -1 (MCP-1) in the spinal cord lesions in HTLV-I-associated myelopathy. *Acta Neuropathol.* 1996;91(4):343-50.

Umehara F, Yoshino S, Arimura Y, Fukuoka T, Arimura K, Osame M. Posterior interosseous nerve syndrome with hourglass-like fascicular constriction of the nerve. *J Neurol Sci.* 2003 Nov 15;215(1-2):111-3.

Urabe T, Sano K, Tanno M, Mizoguchi J, Otani M, Lee MH, Takasaki T, Kusakabe H, Imagawa DT, Nakai M. A non-radioisotopic reverse transcriptase assay using biotin-11-deoxyuridinetriphosphate on primer-immobilized microtiter plates. *J Virol Methods.*

1992 Nov;40(2):145-54.

Van Orden, K; Yan, JP; Ulloa, A; Nyborg, JK. Binding of the human T-cell leukemia virus Tax protein to the coactivator CBP interferes with CBP-mediated transcriptional control. *Oncogene.* 1999;**18**:3766–3772.

Verdonck K, González E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. *Lancet Infect Dis.* 2007 Apr;7(4):266-81.

Waldmann TA, White JD, Goldman CK, *et al.* The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. *Blood* 1993;82:1701–12.

Weiss RA. The discovery of endogenous retroviruses. *Retrovirology.* 2006 Oct 3;3:67.

Williams AE, **Fang CT**, **Slamon DJ**, **Poiesz BJ**, **Sandler SG**, **Darr WF 2nd**, **Shulman G**, **McGowan EI**, **Douglas DK**, **Bowman RJ, et al**. Seroprevalence and epidemiological correlates of HTLV-I infection in U.S. blood donors. *Science.* 1988 Apr;240(4852):643-6.

Wu E, **Dickson DW**, **Jacobson S**, **Raine CS**. Neuroaxonal dystrophy in HTLV-1-associated myelopathy/tropical spastic paraparesis: neuropathologic and neuroimmunologic correlations. *Acta Neuropathol.* 1993;86(3):224-35.

Wu, K; Bottazzi, ME; de la Fuente, C; Deng, L; Gitlin, SD; Maddukuri, A; Dadgar, S; Li, H; Vertes, A; Pumfery, A; Kashanchi, F. Protein profile of tax-associated complexes. *J Biol Chem.* 2004;**279**:495–508.

Yamaguchi K, **Yul LS**, **Shimizu T**, **Nozawa F**, **Takeya M**, **Takahashi K**, **Takatsuki K**. Concurrence of lymphoma type adult T-cell leukemia in three sisters. *Cancer.* 1985 Oct 1;56(7):1688-90.

Yamaguchi K, **Matutes E**, **Catovsky D**, **Galton DA**, **Nakada K**, **Takatsuki K**. Strongyloides stercoralis as candidate co-factor for HTLV-I-induced leukaemogenesis.

Lancet. 1987 Jul 11;2(8550):94-5.

Yamaguchi K. Human T-lymphotropic virus type I in Japan. *Lancet.* 1994 Jan 22;343(8891):213-6.

Yamamoto S, Folks TM, Heneine W. Highly sensitive qualitative and quantitative detection of reverse transcriptase activity: optimization, validation, and comparative analysis with other detection systems. *J Virol Methods.* 1996 Sep;61(1-2):135-43.

Yamaoka, S; Inoue, H; Sakurai, M; Sugiyama, T; Hazama, M; Yamada, T; Hatanaka, M. Constitutive activation of NF-kappa B is essential for transformation of rat fibroblasts by the human T-cell leukemia virus type I Tax protein. *Embo J.* 1996;15:873–887.

Yasunaga, J; Sakai, T; Nosaka, K; Etoh, K; Tamiya, S; Koga, S; Mita, S; Uchino, M; Mitsuya, H; Matsuoka, M. Impaired production of naive T lymphocytes in human T-cell leukemia virus type I-infected individuals: its implications in the immunodeficient state. *Blood.* 2001;**97**:3177–3183.

Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. *AIDS.* 2004 May 21;18(8):1101-8.

Yoshida M. Multiple viral strategies of htlv-1 for dysregulation of cell growth control. *Annu Rev Immunol.* 2001;**19**:475–496.

Yoshie O, Fujisawa R, Nakayama T, *et al.* Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. *Blood* 2002;99:1505–11.

Yoshioka A, **Hirose G**, **Ueda Y**, **Nishimura Y**, **Sakai K**. Neuropathological studies of the spinal cord in early stage HTLV-I-associated myelopathy (HAM). *J Neurol Neurosurg Psychiatry.* 1993 Sep;56(9):1004-7.

7. ACKNOWLEDGEMENTS